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Abstract 
 
 The midbody (MB) is a proteinaceous complex formed between the two daughter 
cells during cell division and is required for the final cell separation event in late 
cytokinesis. After cell division, the post-mitotic midbody, or midbody derivative (MBd), 
can be retained and accumulated in a subpopulation of cancer cells and stem cells, but not 
in normal diploid differentiated cells. However, the mechanisms by which MBds 
accumulate and function are unclear. Based on this, I hypothesize that the MBd is 
degraded by autophagy after cell division in normal diploid differentiated cells, whereas 
non-differentiated cells have low autophagic activity and would accumulate MBds. 
Indeed, I found this to be the case. MBd degradation occurred soon after cytokinesis in 
differentiated cells that possess high autophagic activity. Specifically, I found MBd 
degradation to be mediated by binding of the autophagy receptor, NBR1, to the MB 
protein Cep55. Moreover, by performing proteomic analysis of NBR1 interactions I 
found additional MB-localized proteins that are potential substrates for NBR1. In contrast 
to differentiated cells, stem and cancer cells have low autophagic activity thus MBds 
evade autophagosome encapsulation and accumulate. To examine whether MBds can 
define the differentiation status of a cell, we depleted NBR1 from differentiated 
fibroblasts causing an increase in MBd number. Strikingly, under these conditions, 
reprogramming of fibroblasts to pluripotent stem cells is increased. Equally interestingly, 
cancer cells with increased MBds have increased in vitro tumorigenicity. In conclusion, 
this study gives an insight into the fates of post-mitotic midbodies and also suggests a 
vi
non-cytokinetic role of midbodies in enhancing pluripotency in stem cells and cancer 
stem cells. 
vii
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Chapter I 
 
General Introduction 
 
Cytokinesis, an essential step at the termination of cell division, requires the 
midbody, a proteinaceous organelle-like structure. The midbody contains proteins 
indispensable for cytokinesis completion, chromosome segregation, and vesicle 
trafficking (Skop et al., 2004). Some of the midbody proteins have been implicated in 
stem cell maintenance and cancer progression (Strebhardt and Ullrich, 2006; Chen et al., 
2007; O'Brien et al., 2010); however, whether the midbody itself regulates these 
processes is unknown. Here, I focused on understanding the role of autophagy in 
regulating post-mitotic midbody fate thus revealing its non-mitotic functions. Our results 
demonstrated a role of selective autophagy in the removal of the post-mitotic midbody 
(or midbody derivative, MBd), and also suggested potential functions of these organelles 
in stem and cancer cells. 
Midbody formation and its function in cytokinesis 
The midbody was first described by Walther Flemming more than a century ago 
as a chromophilic structure between two dividing daughter cells (a.k.a. flemming body). 
Since then, with the aid of microscopy, studies have provided more details into midbody 
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structure and dynamics. The midbody is derived from the midzone, an area assembled 
during anaphase in the center of the spindle where the spindle microtubules from 
opposite poles overlap. Assembly of the midzone involves primarily the centralspindlin 
complex composed of MKLP1, a kinesin-like protein, and MgcRacGAP, a Rho GTPase 
activating protein (Mishima et al., 2002; Pavicic-Kaltenbrunner et al., 2007). As 
cytokinesis initiates, centralspindlin promotes the activation of RhoA, leading to cleavage 
furrow formation and ingression at the cell equator (reviewed in Fededa & Gerlich, 2012; 
Green et al., 2012). This constriction proceeds until the spindle midzone is compacted 
into a single large microtubule bundle with an electron-dense structure in the center. 
Together, the microtubule bundle and the electron-dense structure form the midbody.  
Studies over the years have revealed a function for the midbody in localizing 
factors and coordinating events required for faithful abscission, a membrane remodeling 
and fusion event that separates the daughter cells. Abscission requires selective transport 
of endocytic and secretory vesicles as well as the association of the ESCRT complex to 
the midbody. Depletion of proteins essential for tethering these vesicles at the midbody, 
such as centriolin and Cep55 for secretory vesicles, or FIP protein family and ARF6 for 
Rab11-containing endosomes, causes abscission failure (Gromley et al., 2005; Wilson et 
al., 2005; Fielding et al., 2005; Zhao et al., 2006). ESCRT complex recruitment to the 
midbody also requires Cep55 (Morita et al., 2007; Carlton et al., 2007; Lee et a., 2008). 
While the aforementioned findings suggest that the midbody directs the location of the 
cleavage site within the intercellular bridge, there is also compelling evidence that the 
midbody must interact with the cleavage furrow through centralspindlin to ensure 
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completion of cytokinesis (Lekomtsev et al., 2012). Because of these diverse functions, 
the midbody lies at the heart of the cytokinetic mechanism. 
Fates of post-mitotic midbodies 
Previous work showed that after cell division, midbodies (MBs) appeared to be 
jettisoned from cells (Mullins et al., 1977; Dubreuil et al., 2007) or retained within cancer 
cells (Gromley et al., 2005; Goss et al., 2008; Pohl and Jentsch, 2009). Due to these 
observations and that MBd fates were not systematically tested in cells of different 
origins, colleagues in Doxsey laboratory and I examined (in chapter II) over fifteen 
cultured cell lines and several human and mouse stem cell niches (mouse neocortex, 
seminiferous tubules, human hair follicles) and found that MBd fates are distinct in 
different cell types (Fig. 2-3 and 2-4a). In stem cells, induced pluripotent stem cells 
(iPSCs) and cancer cells, MBds were retained and accumulated. By contrast, normal 
proliferating non-cancer, non-stem cells did not accumulate MBds. Most interesting, 
MBds were higher in cancer stem cells and cancer cells with higher tumorigenic potential. 
When MBd-rich human embryonic stem cells were induced to differentiate, MBds weresignificantly decreased. When differentiated cells were induced to becomepluripotent, MBds were significantly increased. These findings thus suggested arelationship between the accumulation of MBds and the pluripotency andtumorigenic potential of cells. MBds can be degraded by autophagy (Pohl andJentsch, 2009); however, how autophagy interfaces with MBd degradation upondifferent cell physiological states has not been illuminated.  
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Autophagy function and regulation  
Autophagy is an evolutionarily conserved degradative mechanism that involves 
the formation of autophagic vacuoles (autophagosome) around cargoes to ensure their 
delivery to lysosomes for degradation. In virtually all cells autophagy is constitutively 
active at a low basal level in the absence of stress to degrade and recycle unwanted 
cellular components contributing to cellular homeostasis. Upon stress conditions, 
autophagy can be activated to serve as a survival response. Known stimuli that induce 
autophagy include: nutrient starvation, endoplasmic reticulum stress, and pathogen 
invasion. Autophagy also contributes to cell makeover or tissue remodeling, as in oocyte 
fertilization (Tsukamoto et al., 2008; Sato & Sato 2011) or during Drosophila 
morphogenesis (Berry et al., 2007). Because of its wide spectrum of targets, autophagy 
participates in many physiological processes, including embryogenesis, innate and 
adaptive immunity, cancer progression, neurodegeneration, and aging (reviewed in 
Cecconi and Levine, 2008; Levine and Kroemer, 2008). 
 Recent studies have revealed the molecular mechanisms of autophagy in yeast 
and other eukaryotes, and most of these mechanisms are conserved (reviewed in Yang 
and Klionsky, 2010; Mizushima et al., 2011; Fig. 1-1). In mammals, the formation of the 
autophagosome requires membrane targeting of Atg8 homologues (LC3, gate16,  
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gabarap), which is mediated by two ubiquitin-like conjugations involving Atg3, Atg4, 
Atg5, Atg7, Atg10, Atg12, and Atg16. Upstream, signaling complexes PI3K III and 
ULK1 positively regulate autophagy. Type III PI3K complex contains the Vps34 lipid 
kinase, p150, Beclin 1, and ATG14, and is essential for the nucleation of pre-
autophagosomal membrane. The ULK1 complex, which comprises the kinase ULK1, 
Atg13, FIP200/RB1CC1, and Atg101, is repressed by mTOR kinase under nutrient-rich 
conditions but becomes activated to direct translocation of the PI3K III complex to the 
nucleation site (Itakura, 2010; Matsunaga et al., 2010). Other signaling pathways that 
control autophagy also exist, some of them inhibit autophagy through PI3K III complex 
and their inhibition activates autophagy under normal nutrient-rich conditions (Lipinski et 
al., 2010). 
Selective autophagy and its players 
Autophagy was first described as a non-selective, bulk cytoplasmic degradation 
system. However, recent studies have demonstrated autophagy to be a highly organized 
specific degradation system given that the degradation of autophagic cargo happens 
selectively under nutrient-deficient conditions (Kristensen et al., 2008; Kraft et al., 2008; 
Gao et al., 2010). For instance, a mass spectrometry-based quantitative proteomics 
indicates that autophagic cargoes are degraded in an orderly manner- the degradation of 
cytosolic proteins occurs more rapidly than the protein complexes and organelles 
(Kristensen et al., 2008). Also, mature ribosomes are selectively modified by the 
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Ubp3p/Bre5p ubiquitin protease and removed by autophagy upon nutrient starvation in 
Saccharomyces cerevisiae (Kraft et al., 2008). Moreover, autophagy receptors that confer 
cargo specificity have been identified. 
Selective autophagy receptors identified in mammals to date include 
p62/SQSTM1, NBR1, NDP52, optineurin, and c-CBL (Bjorkoy et al., 2005; Pankiv et al., 
2007; Kirkin et al., 2009a; Thurston et al., 2009; Sandilands et al., 2011; Wild et al., 
2011). Owing to their ubiquitin-binding domain and LC3-interacting motif, autophagy 
cargo receptors are able to bring selected ubiquitin-positive substrates into close vicinity 
of the autophagy machinery. Among these receptors, p62 is the most studied and is 
known to be involved in various selective forms of autophagy, including the degradation 
of mitochondria, peroxisome, misfolded protein aggregates, and invading pathogens 
(Kirkin et al., 2009b). p62 often acts in concert with other receptors. For instance, both 
p62 and NBR1 localize to ubiquitinated protein aggregates and depletion of either protein 
affects aggregate clearance (Kirkin et al., 2009a). Similarly, p62, NDP52, and optineurin 
are independently recruited to ubiquitinated Salmonella typhimurium and all three 
receptors are required for restricting the intracellular growth of the bacteria (Thurston et 
al., 2009; Zheng et al., 2009; Cemma et al., 2011; Wild et al., 2011). However, it is not 
clear why multiple receptors are required and how the receptors are chosen/involved in a 
given form of selective autophagy.  
In addition to autophagy receptors, several adaptor proteins have been implicated 
in selective autophagy (Gamerdinger et al., 2009; Filimonenko et al., 2010; Ogawa et al., 
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2011). These proteins, although not directly associated with the ubiquitin or Atg8/LC3-
homologues, are able to bind other autophagy-related proteins and may thus bridge 
substrates to autophagosomes. One example is Alfy, the autophagy-linked FYVE protein 
that binds to both p62 and Atg5 and participates in the clearance of mutant Hutingtin, an 
aggregation-prone protein implicated in neurodegeneration (Filimonenko et al., 2010). It 
was found that the sub-cellular distribution of Alfy to ubiquitinated aggregates relies on 
its binding to p62 (Clausen et al., 2010), whereas Alfy’s ability to accelerate aggregate 
removal depends on its Atg5 interaction (Filimonenko et al., 2010). It is proposed that 
Alfy functions as a scaffold to bring the Atg5-Atg12-Atg16L complex and LC3 together 
to ubiquitinated substrates, hence promoting aggregate degradation (Filimonenko et al., 
2010). For other adaptor proteins, BAG3 (BCL-2-associated athanogene 3) acts in 
conjunction with p62 to degrade protein aggregates while Tecpr1 (Tachylectin-II-like 
beta-propeller domain 1) targets Shigella in an Atg5-dependent manner (Gamerdinger et 
al., 2009; Ogawa et al., 2011).  
Selective autophagy regulation by post-translational modification  
As mentioned in the last section, ubiquitination of the substrates can provide 
specificity to an autophagy receptor. Indeed, ubiquitin is often co-localized with 
autophagy substrates before substrate degradation (Pankiv, et al., 2007; Clausen et al., 
2010). Ubiquitin attachment or co-expression appears to be sufficient to target small 
substrate like long-lived cytosolic proteins and large substrates like peroxisomes or 
protein inclusions for autophagic degradation (Kim et al., 2008; Tan et al., 2008). 
However, although diverse types of substrates are targeted by ubiquitination, substrate 
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selection does not always require ubiquitination. Degradation of mutant superoxide 
dismutase 1 (SOD1), mutant STAT5A, Sindbis viral capsid, and P granules of 
Caenohabditis elegans are examples of ubiquitin-independent autophagic degradation 
(Gal et al., 2009; Zhang et al., 2009; Orvedah et al., 2010; Ogawa et al., 2011; Watanabe 
and Tanaka, 2011).  
 Recently, protein phosphorylation has been linked to selective autophagy. For 
instance, the autophagy receptor, Optineurin, displays higher binding affinity to LC3 and 
promotes autophagy of Salmonella when a residue adjacent to its LC3-interacting motif is 
phosphorylated (Wild et al., 2011). Similarly, phosphorylation of the ubiquitin-binding 
domain of p62 increases its affinity to polyubiquitin and promotes degradation of 
polyubiquitinated proteins (Matsumoto et al., 2011). These studies thus indicate a general 
role for phosphorylation in controlling the function of autophagy receptors. Moreover, 
they reveal another layer of spatiotemporal regulation in controlling the autophagy 
signaling networks. As LC3-interacting motifs and ubiquitin-binding domains are 
common features of the autophagy receptors, it would be tempting to speculate a broader 
effect of phosphorylation on the process of selective autophagy. 
 Intrigued by the phenomenon of MBd accumulation and considering its potential 
importance, we have set out to study the fate and function of these organelles after 
cytokinesis. In chapter II, we will describe how the fates of post-mitotic midbodies are 
regulated differentially by NBR receptor-mediated autophagy, leading to their 
accumulation in cells with differentiating potential. We will also describe the potential 
10
functions of post-mitotic midbodies as suggested by the results of NBR1 depletion. In 
chapter III, we will present the first proteomics study on the NBR1-interaction network, 
which reveals several new potential MBd substrates for NBR1, as well as modification 
events that may regulate NBR1‘s function in autophagy.  
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CHAPTER II 
 
MIDBODY ACCUMULATION THROUGH EVASION OF AUTOPHAGY 
CONTRIBUTES TO CELLULAR REPROGRAMMING AND 
TUMORIGENICITY 
 
 
 
 
Fig. 2-1a-d, f, and g, Fig. 2-2, Fig. 2-3 (except d and h), part of Fig. 2-4a, Fig. 2-4b-d, Fig. 2-5b, 
and 5e (H1, H9, and HeLa), Fig. 2-7e, Fig. 2-S1, and Fig. 2-S3 were contributed by Dr. Chun-
Ting Chen.  
 
Fig. 2-1e, Fig. 2-3d, Fig. 2-6e-g, Fig. 2-8d and e, Fig. 2-S2, and Fig. 2-S4 were contributed by Dr. 
Desiree Baron. 
 
Cara Weismann contributed to part of Fig. 4a. 
 
Dr. Tamer Onder and Dr. Sabine Loewer contributed to Fig. 2-8a-b, and Table 2-S1. 
 
Tse-Chun Kuo contributed to Fig. 2-3h, Fig. 2-4a (RPE, DLD-1 and MCF-7), Fig. 2-5c-e (RPE-1, 
MCF-7, and HeLa), Fig. 2-6a-d, Fig. 2-7a-d, Fig. 2-8a-c, and f, Fig. 2-S5-8, Table 2-S1, and 
Table 2-S2. 
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ABSTRACT 
The midbody (MB) is a singular organelle formed between daughter cells during 
cytokinesis and required for their final separation. MBs persist in cells long after division 
as midbody derivatives (MBds), but their fate is unclear. Here we show that MBds are 
inherited asymmetrically by the daughter cell with the older centrosome. They selectively 
accumulate in stem cells, induced pluripotent stem cells (iPSCs) and potential cancer 
‘stem cells’ (CSCs) in vivo and in vitro. MBd loss accompanies stem cell differentiation, 
and involves autophagic degradation mediated by binding of the autophagic receptor, 
NBR1, to the MB protein Cep55. Differentiating cells and normal dividing cells do not 
accumulate MBds and possess high autophagic activity. Stem cells and cancer cells 
accumulate MBds by evading autophagosome encapsulation and exhibit low autophagic 
activity. MBd enrichment enhances reprogramming to iPSCs and increases in vitro 
tumorigenicity of cancer cells. These results suggest unexpected roles for MBds in stem 
cells and CSCs.  
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INTRODUCTION 
Cell division culminates in the separation of two genetically identical daughter cells 
(Eggert et al., 2006). During division, cell fate determinants segregate asymmetrically to 
stem cell progeny (Neumüller and Knoblich, 2009). The two spindle poles organized by 
differentially-aged centrosomes contribute to this asymmetry (Doxsey et al., 2005; 
Neumüller and Knoblich, 2009) in that the older centrosome is inherited by the daughter 
cell that retains the stem cell fate (Yamashita et al., 2003, 2007; Wang et al., 2009). 
Abscission completes cell division by severing the intercellular bridge between the 
two future daughter cells (Eggert et al., 2006; Barr and Gruneberg, 2007). Within the 
intercellular bridge lies the midbody (MB), a large proteinaceous organelle (Mullins, J.M. 
and Biesele, 1977; Gromley et al., 2005; Barr and Gruneberg, 2007; Steigemann et al., 
2009) that was previously thought to detach from cells and disintegrate extracellularly as 
a remnant (Mullins, J.M. and Biesele, 1977; Barr and Gruneberg, 2007). Recent studies 
show that post-abscission MBs or MB derivatives (MBds) can be retained by daughter 
cells, suggesting alternative fates for these organelles (Gromley et al., 2005, Goss and 
Toomre, 2008; Pohl and Jentsch, 2009).  
The fate and function of MBds is unclear. In neural progenitors, MBds possess the 
putative stem cell marker CD133/prominin-1 and are proposed to participate in 
intercellular signaling during neural development (Marzesco et al., 2005; Dubreuil et al., 
2007). MBds can be degraded by autophagy (see below, Pohl and Jentsch, 2009), but the 
relationship between MBd loss or retention and the physiological state of cells is 
14
unknown. 
During autophagy (macroautophagy), double membrane-bound autophagosomes 
assemble, engulf cytoplasmic material, and fuse with lysosomes for degradation 
(Mizushima and Klionsky, 2007; Yorimitsu and Klionsky, 2007; Mizushima et al., 2008; 
Levine, B. and Kroemer, 2008). Autophagy is required for cellular homeostasis, 
eliminating defective ubiquitin-tagged proteins and organelles (Kuma et al., 2004, 
Mizushima and Klionsky, 2007; Yorimitsu and Klionsky, 2007; Levine and Kroemer, 
2008), clearing cell fate determinants and cell remodeling (Fimia et al., 2007; 
Tsukamotoet al., 2008; Cecconi and Levine, 2008). Defects in autophagy contribute to 
many disorders, including neurodegeneration (Hara et al., 2006), hepatomegaly (Komatsu 
et al., 2005) and aging (Mizushima et al., 2008, Levine and Kroemer, 2008).  
Here we show that MBds accumulate in stem cells and are lost upon differentiation. 
They are selectively degraded by linking the NBR1 autophagic receptor to the Cep55 MB 
protein. MBds accumulate by evasion of autophagosome encapsulation, asymmetric 
inheritance, and maintenance of low autophagic activity. Reprogramming efficiency and 
in vitro tumorigenicity are increased following experimental elevation of MBd levels 
suggesting non-mitotic roles for these organelles in stem and cancer cells. 
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RESULTS 
Post-mitotic midbodies accumulate within cells  
Multiple MBds were observed in subpopulations of cells by immunofluorescence 
(IF), but their precise location was unclear (up to 20; Fig. 2-1a, b). Three-dimensional 
reconstruction of immunofluorescent images revealed multiple MBds inside polarized and 
nonpolarized cells (Fig. 2-1c, d). Immuno-electron microscopy confirmed this 
localization and revealed ultrastructural features characteristic of MBds (Fig. 2-1e, 
Mullins and Biesele, 1977; Dubreuil et al., 2007). About 70% of cell-associated MBds 
were trypsin-resistant, suggesting that they were intracellular (Fig. 2-1f). This 
intracellular localization of MBds suggested that they might accumulate in cells through 
successive divisions (below).  
MBds were also released from cells. In 2-day co-cultures of HeLa cells stably 
expressing either monomeric RFP (cytoplasmic marker) or MKLP1-GFP (MB marker), 
about 7% of MKLP1-GFP+ MBds associated with RFP+ cells (Fig. 2-1g). Such free 
MBds were also generated by other cell types (e.g., human adult fibroblasts, HeLa; 1-
10%). These observations resolve the conflict of previous studies suggesting that MBds 
are either retained and degraded (Gromley et al., 2005; Goss and Toomre, 2008; Pohl and 
Jentsch, 2009) or released as remnants after abscission (Mullins and Biesele, 1977). We 
show that MBds accumulate in some cells (Fig. 2-1a-d) but not others, and it is this cell 
type-specific difference in MBd-accumulation that is the focus of this study. 
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Figure 2-1 MBds accumulate within cells. (a, b) Multiple MBds associate with a PC3 
cell (a) and a B-lymphoblast (b). Insets (a) MBd labeling and (b) merged phase-contrast 
image with MBd labeling to show cell boundaries. MKLP1, MBd marker (a, b; red); 
CD44, membrane (a; green); DAPI, DNA (a; blue). Bar, 5 µm (a) and 2 µm (b). (c, d) 
Three-dimensional reconstruction of polarized cells in a monolayer (c) and a HeLa cell 
(d) show intracellular MBds. (c) ZO-1, tight junction; MKLP1, MBds. Bar, 2 µm. 
Enlargement (c, bottom) of box (c, top) shows five MBds (arrows). (d) Wheat germ 
agglutinin, plasma membrane (red); MKLP1-GFP, MBds (green); DAPI, DNA (blue). 
Bar, 5 µm. (e) Electron micrograph of a MBd in a permeabilized MCF-7 cell showing 
immungold labeling with MKLP1 antibodies. Inset, lower magnification of the MBd 
(boxed) in cell; nucleus, right. Bar, 200 nm. (f) Time-lapse images during extracellular 
trypsin treatment of HeLa cells show retention of most MBds (MKLP1-GFP, red). Two 
MBds (yellow arrows) are lost upon treatment, suggesting digestion and/or dissociation. 
Time (hr:min) post-trypsin. Bar, 5 µm. (g) Two-day co-cultures of HeLa cell expressing 
either MKLP1-GFP (MBd marker) or cytosolic RFP. Green MBds (arrows) associated 
with red cells (asterisk) indicate post-mitotic transfer of MBds between cells. Bar, 10 µm. 
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MBds are inherited by the cell with the older centrosome  
Multiple MBds often clustered around the centrosome or spindle pole (Gromley et 
al., 2005 and data not shown), reminiscent of MBd-sized aggresomes, which segregate to 
one daughter cell under control of centrosomes (Johnston et al., 2002; Rujano et al., 
2006). Moreover, centrosome age-dependent differences in signaling were observed late 
in cytokinesis (Anderson and Stearns, 2007). These centrosome age-related differences 
led us to examine the relationship between centrosomes and MBd inheritance.  
In G1, the centrosome contains one mother centriole (MC) and one daughter 
centriole (DC; reviewed in Doxsey et al., 2005). After centriole duplication, three 
generations of centrioles are present: an older mother, a younger mother and two new 
daughters (Doxsey et al., 2005; Anderson and Stearns, 2007). The centrosome with the 
older MC is termed the older centrosome (Yamashita et al., 2007; Wang et al, 2009). 
GFP-tagged centrin1 (CETN1-GFP; Piel, et al., 2000) expressed in mitotic HeLa cells 
was brightest at one of the four centrioles (92.2% of cells, n=116; Fig. 2-2a) and turned 
over very slowly (FRAP t1/2 ~4 hours and Wang et al., 2009). The brightest centriole 
remained so from metaphase to late cytokinesis (91.3% of cells, n=46; supplementary 
information, Fig. 2-S1a), suggesting that it was the older MC. This was confirmed by 
staining with the older centrosome marker, hCenexin1 (~90% of HeLa and MCF-7 cells, 
n=143 and n=347, respectively; Fig. 2-2b; Anderson and Stearns, 2007). Several other 
centriole antigens also showed intrinsic age-related differences in labeling 
(supplementary information, Fig. 2-S1b). 
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Figure 2-2 MBds are preferentially inherited by the cell with the older centrosome. 
(a) CETN1-GFP signal is brighter in upper centrosome/spindle pole of a mitotic spindle. 
The merged DIC image with CETN1-GFP labeling at two centrosomes shows metaphase 
chromosome. Insets (lower left, upper right), enlargement and semi-quantitative 
integrated intensity profile of centrioles. Bar, 5 µm. (b) The brighter CETN1-GFP signal 
represents the older centrosome as it co-stains more intensely for hCenexin1 and remains 
more intense throughout cell division (supplementary information, Fig. 2-S1a). Bar, 5 
µm. Lower left, merge. (c, d) Time-lapse images show that the mitotic MB is 
preferentially inherited by the daughter cell with the older centrosome in HeLa cells (c) 
and hESCs (d). Cells were imaged at the indicated times (hr:min) from telophase by 
phase-contrast microscopy (c) and from metaphase by DIC microscopy (d). Middle panel 
of (c) and left panel of (d), CETN1-GFP at centrosomes; enlargements and integrated 
intensity profiles show the daughter cell having the older centrosome (c, upper; d, lower) 
inherits the MBd (Time-lapse images: 9:59 in c; lower right image in d). Mitotic MB and 
MBds (c, d; arrows). MKLP1, MBd marker (red); a-tubulin, mitotic MB and cell 
boundary marker (green); DAPI, DNA (blue). Bars, 10 µm (c, d).  
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Using CETN1-GFP to identify the older MC; bright-field imaging to follow MB 
dynamics in living cells; and immunofluorescence to confirm MBd inheritance, we 
determined that MBds were preferentially inherited by the cell with the older centrosome. 
This was observed in pluripotent human embryonic stem cells (hESCs; 83.3% of H9, 
n=18; Fig. 2-2d), immortalized somatic cells (91.3% of hRPE-1, n=23) and cancer cells 
(U2OS: 84.6%, n=13; HeLa: 75.0%, n=24; Fig. 2-2c). We conclude that most inherited 
MBds are asymmetrically transferred to the daughter cell with the older centrosome in 
several cell types.  
MBds accumulate in stem cells in vivo  
Other studies have shown that the older centrosome is asymmetrically inherited by 
the stem cell during asymmetric divisions in the Drosophila male germline (Yamashita, 
et al., 2007) and the mouse neocortex (Wang et al., 2009). The association of the older 
centrosome with both MBds and stem cell divisions led us to ask whether MBds were 
found in stem cell niches. To address this, we determined the localization of MBds in 
human and mouse tissues. In seminiferous tubules of testes, MBds were confined to the 
basal compartment, the site of germline stem cells and their mitotic progeny (both 
capable of self-renewal; Fig. 2-3a, up to 8 puncta/cell, 5-mm section; Oatley and Brinster. 
2008; Barroca et al., 2009). Electron microscopy also revealed multiple cytoplasmic 
structures with features characteristic of MBds within these cells (Fig. 2-3b, c). 
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In the ventricular zone (VZ, Sox2+31) of embryonic mouse brains, CD133-labeled 
MBds were associated with neural progenitors (Fig. 2-3d and supplementary information, 
Fig. 2-S2; Marzesco,et al., 2005; Dubreuil et al., 2007). During asymmetric divisions, 
intracellular MBds were usually found in ventricle-facing daughter cells (progenitors; 
75%, n=8) and not in daughters with presumed committed fates (Wang et al., 2009). 
MBds in the human hair follicle were also confined to a subpopulation of cells in the stem 
cell niche, the bulge (Morris et al., 2004), suggesting distinct properties of this 
subpopulation (Fig. 2-3e, f). MBds were also enriched in b1-integrin+ (Conboy et al., 
2010) mouse skeletal muscle progenitors (SMPs; 4-fold) over non-SMP cells. These 
observations suggested that MBds were selectively retained and accumulated during 
successive stem cell divisions in vivo. 
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Figure 2-3 MBds accumulate in stem cells in vivo and in vitro. (a) Histological section 
through mouse seminiferous tubules labeled for MKLP1 shows several MKLP1+ puncta 
in cells of the basal layer where stem cells reside. Bar, 20 µm. Inset, enlargement of the 
cell (arrow) (b, c) Electron micrographs of mitotic MB (b, arrow) and multiple MB-like 
structures in interphase cells with similar shape and size in a juxtanuclear position (c, 
arrows) in basal cells of mouse seminiferous tubules. N, nucleus. Bars, 1 µm. (d) 
Representative planes of a neural progenitor cell in the ventricular zone (Sox2+, left-
bottom panel) of an E13.5 mouse brain show that an intracellular MBd (asterisk) is 
associated with the ventricle-facing daughter in the asymmetrically dividing cell (top 
row). The bottom row emphasizes the position of paired chromosomes in a dividing 
anaphase cell. CD133, MB/MBd marker (green); Na-K-ATPase, cell-border marker (red); 
DRAQ5, DNA (blue); DAPI, DNA. Ventricle (V). Bar, 5 µm. Note that abscission occurs 
apically in these cells. (e) A histological section through a hair follicle (left, phase-
contrast microscopy) stained for the stem cell marker keratin 15 to identify the bulge 
region (dotted box), the stem cell niche. DNA stain (DAPI) and the phase-contrast image 
show full follicle architecture. (f) Upper panels show MBd-accumulating cells in the 
bulge region (boxed) colabeled with K15 and MKLP1. Enlargements (lower panels) of 
the boxed region highlight a cell with four MBds (asterisks). N, nucleus. Bar, 5 µm. (g-i) 
Quantitative analysis and representative images show a decrease in MBd-accumulating 
cells upon the differentiation of pluripotent stem cells (g, H1-OGN) to fibroblast-like 
cells (h, dH1f), and an increase in MBd-accumulating cells after reprogramming 
differentiated cells (h) to induced pluripotent stem cells (i, dH1f-iPS). (g-i) numbers refer 
to mean ± s.d., n=3. MKLP1, MBds; ZO-1, tight junctions; a-tubulin, microtubules; 
Aurora B, MBs. Bar, 10 µm.  
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MBds accumulate in stem cells in vitro 
To rigorously test the idea that MBds are selectively inherited by stem cells, we 
examined MBd fate during stem cell differentiation and somatic cell reprogramming. 
MBd ‘accumulation’ was assessed by counting cells with >1 MBd, as all cells can 
transiently acquire one MBd after abscission (below). MBd-accumulation decreased ~8-
fold upon differentiation of hESCs (H1-OGN) to fibroblast-like cells (dH1f; Fig. 2-3g, h). 
Differentiation was judged by loss of embryonic stem cell markers (Oct4, Sox2, Klf4, 
Nanog) and gain of the CD13 differentiation marker (Park et al., 2008; Chan et al., 2009). 
In contrast, MBd-accumulation increased ~7-fold after reprogramming dH1f cells to 
iPSCs (dH1f-iPS; Fig. 2-3h, I; Zwaka and Thomson, 2003; Park et al., 2008). We 
conclude that MBd-accumulation in vitro reflects that observed in vivo, and can be 
manipulated by altering the potency status of cells.  
MBd-accumulation is enhanced in tumor-derived cells 
We next examined differences in MBd-accumulation among cell lines derived from 
stem cells, normal dividing cells and cancer cells (Fig. 2-4a). MBd-accumulation was low 
in primary and telomerase-immortalized normal cells and significantly higher in hESCs 
and iPSCs (~7-fold on average; Fig. 2-4a). Most cancer cells exhibited even higher levels 
of MBd-accumulation. For example, MBd-accumulation in tumorigenic MCF-10AT and 
MCF-10CA1a cells was much higher than in the normal MCF-10A parental line. The 
common ability of stem cells and cancer cells to accumulate MBds, express stem cell 
25
markers (Visvader and Lindeman, 2008) and possess stem cell properties (O'Brien et al., 
2007; Pece et al., 2010) suggests a relationship between MBd-accumulation, 
tumorigenicity and cancer ‘initiating’ or ‘stem’ cells defined by the CSC theory (Pardal et 
al., 2003).  
MBd-accumulation does not correlate with cell proliferation rate 
A simple explanation for cell type-specific differences in MBd-accumulation is 
variability in proliferation rates. Slower division rates could allow more time for MBd 
degradation, as recently proposed (Pohl and Jentsch, 2009). However, we observed no 
correlation between population doubling-time and MBd-accumulation (Fig. 2-4a). It was 
still possible that MBd-accumulating cells cycled faster than the bulk population. 
However, a cohort of cells pulse-labeled with EdU (Salic and Mitchison, 2008) showed a 
proportional decrease in EdU intensity, reflecting dilution of dye after successive 
divisions (Fig. 2-4b) and indicating that MBd-accumulating and non-accumulating 
subpopulations had similar cycling rates (Fig. 2-4c, d).  
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Figure 2-4 MBd-accumulation is high in stem cells and subpopulations of cancer 
cells and does not correlate with cell doubling time. (a) Percent of cells that 
accumulate MBds (>1) in a range of different cell types, as indicated. Below, doubling-
times of representative cell lines aligned with MBd-accumulation data. Data are presented 
as mean ± s.d.; Cell lines are examined in triplicate (MCF-10A, DLD-1, MCF-10AT, 
MCF-7, H1, and H9), or quadruplicate (e.v. B6 MEFs, HeLa, SAOS-2, and MCF-
10CA1a), except hRPE-1 (n=6), U2OS (n=7) and NCC-IT (n=8). Horizontal line, cell 
lines with different MBd-accumulation potential (14-fold) but similar doubling time. (b) 
Cells pulse-chased with EdU show a decrease in EdU intensity (x-axis) over time (y-
axis), reflecting dilution of dye after cell divisions. (c, d) After a 96-hr chase period, EdU 
levels were compared between cells with MBd numbers of >1, 1, and 0 (y-axis) in HeLa 
(c) and SAOS-2 cells (d). In both cases, no significant differences were noted (c, 
p=0.2101; d, p=0.5609, one-way ANOVA, with at least 800 cells analyzed for each 
experiment, n=3), indicating similar cycling rates among different subpopulations of 
cells. (b-d) Each graph is a representative experiment. Cells analyzed shown by green 
points, median depicted by vertical red lines, and horizontal red lines with ticks illustrate 
the interquartile range. 
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MBd-accumulating cells evade membrane encapsulation of MBds  
We next asked if MBds occupied different sites within MBd-rich and MBd-poor cells. 
To test this, we used the Fluorescence Protease Protection (FPP) assay (Lorenz et al., 
2006) to monitor degradation of MBds following plasma membrane permeabilization and 
protease addition (Fig. 2-5a). Under these conditions, MKLP1-GFP+ MBds were 
degraded in MBd-rich HeLa cells but not in MBd-poor hRPE-1 cells indicating that MBd-
poor cells sequestered MBds in membrane-bound compartments whereas MBd-rich cells 
accumulated them in the cytoplasm (Fig. 2-5b). Importantly, the integrity of intracellular 
organelles was maintained during the course of these experiments (supplementary 
information, Fig. 2-S3).  
Stem cells and cancer cells evade lysosomal degradation of MBds 
The protease resistance of MBds and low MBd-accumulation in MBd-poor hRPE-1 
cells (Fig. 2-4a and 2-5b) suggested that MBds were delivered to a membrane-bound 
compartment for degradation, such as the lysosome. Indeed, MBds were often found 
within LAMP2-labeled lysosomes in MBd-poor cells (Fig. 2-5c; Eskelinen et al., 2003). 
To test this further, we examined the fate of newly-formed MBds in synchronous 
populations of MBd-poor cells (Fig. 2-5d). Three hours after release from mitosis, the 
percent of MBd+ cells (MBd levels) peaked at ~40% (50% being the maximum since half 
the cells were ‘born’ without a MBd). This was followed by a peak in MBd localization to 
lysosomes (~42% at 7 hours; Fig. 2-5d) and then a decrease of MBds to baseline levels  
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Figure 2-5 MBds in stem and cancer cells evade membrane encapsulation and 
lysosomal degradation. (a) Depiction of fluorescence protease protection (FPP) assay. 
Digitonin selectively permeabilizes the plasma membrane but not internal membranes. 
Proteinase K degrades cytoplasmic components but membranous compartments remain 
intact. Under these conditions, MKLP1-GFP-labeled MBds (blue circle) in the cytoplasm 
will be degraded whereas those inside membrane-bound compartments (MBCs) will not. 
(b) MBds in MBd-poor hRPE-1 cells are largely protected (~90% in membranous 
compartments, cells analyzed=10), whereas most MBds in HeLa cells are not (~27%, 
cells analyzed: 11), and are thus degraded in cytoplasm. Bar, 5 mm. (c) Graph depicting 
the presence of MBds in lysosomes upon chloroquine or E64d/pepstatin A (E64d/PepA) 
inhibition in hRPE-1 and HeLa cells, but not in MCF-7 and H9 hESCs. Chloroquine 
treatment of H9 hESCs is not included as it caused differentiation and cell death. A 
representative image of hRPE-1 cells inhibited by chloroquine is shown depicting two 
MBds inside lysosomes. MKLP1 and LAMP2 are used as MBd (red) and lysosome 
(green) markers, respectively. DAPI, DNA (blue). n=100 MBds/treatment in each of the 
biological triplicates. Bar, 5 µm. (d) Graph showing the percent of MBd+ cells (MBd 
levels), the percent of MBds within lysosomes, and the percent of cells exiting cytokinesis 
following synchronization. MKLP1 and LAMP2 are used as markers as in (c). Note that 
MBds are transferred into only one of the two nascent daughter cells after abscission (Fig. 
2-2d), so a 50% maximum will be expected for MBd+ cells. The peak of MBds 
transferred to cells is 3 hours after plating followed by a peak of MBds entering 
lysosomes at 7 hours. (e) Both chloroquine and E64d/PepA treatments increase the 
percent of MBd+ cells in hRPE-1 cells and HeLa cells (chloroquine: p=0.0021 and 
p=0.0187, respectively; E64d/PepA: p=0.0022 and p=0.0043, respectively; n=3 for all 
experiments). In contrast, lysosomal inhibition has no detectable effect on hESCs (H1, 
H9) and MCF-7 cancer cells. Data are presented as mean ± s.d. (c-e), except mean ± 
s.e.m. in hESCs (e).  
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(16-19 hours; Fig. 2-5d). These data and the FPP data suggested that MBds in hRPE-1 
cells entered the cytoplasm, moved into lysosomes and were degraded before the next 
cell cycle (Fig. 2-5b, d).  
If lysosomes are involved in MBd degradation, lysosomal inhibition should increase 
MBd levels. Indeed, when lysosomal activity was inhibited in MBd-poor hRPE-1 cells 
with either chloroquine or E64d/PepA protease inhibitors (Klionsky et al., 2008) MBd 
levels (Fig. 2-5e) and the percent of MBds found within lysosomes (Fig. 2-5c) were 
elevated. In contrast, MBd levels and the percent of MBds in lysosomes in MBd-rich cells 
(hESC, MCF-7; Fig. 2-5c, e) were largely unaffected by lysosomal inhibition (see 
supplementary information, Fig. 2-S4a). The modest increase in MBd+ HeLa cells (Fig. 
2-5e) was consistent with their modest MBd-accumulating ability (Fig. 2-4a). We 
conclude that lysosomal degradation prevents MBd-accumulation in MBd-poor cells, but 
does not play a major role in MBd-rich cells (e.g. stem cells, CSCs) thus allowing MBds 
to accumulate.  
Autophagic degradation controls intracellular MBd levels  
To determine how MBds were directed to lysosomes, we explored pathways leading 
to lysosomal degradation. Reported autophagy levels in MCF-7 and DLD-1 cells (Liang 
et al., 1999; Sato et al., 2007) suggested a relationship between autophagy and MBd fate. 
Low autophagy levels in MCF-7 cells resulting from a deficiency in the autophagy gene, 
BECN1 (also known as Atg6; Liang et al., 1999), are consistent with high MBd-
accumulation (~26-fold over normal cells; Fig. 2-4a). High autophagy levels in DLD-1 
32
cells (Sato et al., 2007) are consistent with low MBd-accumulation (only ~1.8-fold over 
normal cells; Fig. 2-4a). In agreement with this trend was the presence of MBds in 
autophagosomes of MBd-poor cells (Fig. 2-6a).  
Experimental reduction of autophagy activity using MEFs from Atg5-deleted mice 
(Kuma et al., 2004) or by siRNA-mediated depletion of Atg7, increased MBd levels (Fig. 
2-6b, c). Induction of autophagy by rapamycin and lithilum chloride treatment (Sarkar et 
al., 2005; Sarkar et al., 2008) in HeLa cells or by exogenous BECN1 expression in MCF-
7 cells, decreased MBd levels (Fig. 2-6d, e). These results demonstrated the role of 
autophagy in regulating MBd levels in different cell types, and suggested an inverse 
relationship between autophagic activity and MBd-accumulation. This inverse 
relationship was revealed in 12 cell lines by LC3-II (see Methods; Mizushima and 
Yoshimori, 2007; Klionsky et al., 2008) or p62 (Bjorkoy et al., 2005; Komatsu et al., 
2007; Klionsky et al., 2008) -based measurements of autophagic activity (Fig. 2-6f, g and 
supplementary information Fig. 2-S4b). We conclude that MBd levels are, in part, 
modulated by cell type/lineage-specific autophagy (Fig. 2-3g-i, 4a, 6f and 6g). 
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Figure 2-6 Autophagy controls intracellular MBd levels. (a) Single-plane confocal 
images of MBds within LC3-positive autophagosomes in MEFs expressing GFP-LC3 
(left) and in hRPE-1 cells stained for endogenous LC3 (right). MBd markers: Cep55, 
MKLP1, or mgcRACGAP. Autophagosomes: GFP-LC3 or LC3. Note that MKLP1 
(blue) and mgcRACGAP (red) are co-localized (magenta) in the autophagosome (green), 
suggesting that MBds are sorted into autophagosomes. Bars, 2 µm. (b-c) Decreasing 
autophagy levels by deletion of Atg5 gene (left, MEFs) or depletion of Atg7 by siRNA 
(right, HeLa) significantly increases the percent of MBd+ cells (p=0.0019 and p=0.021, 
respectively, n=3). Immunoblots confirm loss of the Atg5-Atg12 conjugation in mutant 
cells and depletion of Atg7 (asterisk). (d-e) Rapamycin (Rapa) and lithium chloride 
(LiCl) co-treatment induces autophagy and decreases the percent of MBd+ cells (left, 
HeLa; p=0.0056, n=3). Immunoblots showing increased LC3-II levels confirm autophagy 
induction. Induction of autophagy by over-expression of Flag-tagged BECN1 reduces the 
percent of MBd+ cells (right, MCF-7; p=0.0008, n=4) (f) Representative immunoblots 
showing high autophagic activity in normal cells and low autophagic activity in stem 
cells and cancer cells. The activity of autophagy was determined by measuring autophagy 
flux: the amount of autophagic cargo that is delivered to lysosomes for degradation. 
Lysosomal protease inhibitors E64d and PepA were used to inhibit lysosomal 
degradation and autophagic cargo, lipidated LC3 (LC3-II), was used to assess autophagic 
flux. U, uninhibited. I, inhibited. Below, the average of the percent change in LC3-II 
levels after lysosomal inhibition from 3 experiments. a-tubulin, loading control. (g) 
Quantification of autophagic flux from 3 experiments in different cell lines. Normal 
dividing cells (MBd-poor) typically have high autophagic flux, whereas stem and cancer 
cells (MBd-rich) have low autophagic flux. The data are presented as mean ± s.d. (b-g). 
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NBR1 is an autophagic receptor for MBd-specific degradation  
To test whether MBd degradation involves non-specific or receptor-mediated 
autophagy pathways (Mizushima, et al., 2008), we investigated the mammalian 
autophagic receptors, p62 (Bjorkoy et al., 2005; Komatsu et al., 2007; Pankiv et al., 
2007) and NBR1 (Kirkin, et al., 2009a; Waters et al., 2009). p62 is implicated in MBd 
clearance (Pohl and Jentsch, 2009), whereas NBR1 is untested. NBR1 and p62 localized 
to mitotic MBs and MBds (Fig. 2-7a, top, data not shown, and Pohl and Jentsch, 2009), 
suggesting that MBd degradation involves receptor-mediated autophagy. NBR1-silencing 
in HeLa cells impeded autophagosomal encapsulation of the MBd (supplementary 
information, Fig. 2-S5) and increased MBd levels to Atg7-silencing levels (Fig. 2-6c and 
2-7b), suggesting that NBR1 is likely a major autophagic receptor for MBd degradation. 
In contrast, p62-deletion (Komatsu et al., 2007) or siRNA-mediated p62 depletion had no 
detectable effect on MBd levels (Fig. 2-7b, c, 2-S6) or NBR1 recruitment to MBds (Fig. 
2-7a, bottom). 
To date, no MBd target(s) for autophagic degradation have been identified. 
Candidate-based screening revealed that endogenous NBR1 co-immunoprecipitated with 
the MB protein Cep55 in hRPE-1 cells (Fig. 2-7d). Cep55 over-expression increased MBd 
levels (Fig. 2-7e, left) and the level of NBR1-negative MBds (Fig. 2-7e, middle), 
presumably through NBR1 sequestration in the cytoplasm (Fig. 2-7e, right). This 
suggested a role of Cep55 in NBR1-mediated MBd degradation. We propose that the 
Cep55/NBR1 interaction couples MBds to the autophagic machinery to control MBd fate.   
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Figure 2-7 NBR1 is a receptor for targeting MBds to the autophagy pathway. (a) 
Single-plane confocal images showing co-localization of the MBd and the autophagic 
receptor, NBR1, in U2OS cells and p62-deleted MEFs. MBd markers: MKLP1 or Cep55. 
Bar, 2 µm. (b) The percent of MBd+ cells is significantly increased following the 
depletion of NBR1 (p=0.022, n=3), but not another autophagic receptor, p62. Co-
depletion of NBR1 and p62 does not further increase MBd levels over NBR1 depletion 
alone. (c) Deletion of the p62 gene does not affect the percent of MBd+ cells. For (b) and 
(c), immunoblots verify protein loss. (d) Co-immunoprecipitation reveals Cep55 and 
NBR1 form a complex. Precipitated proteins and 5% of the input material (Input) were 
analyzed by immunoblotting with antibodies against NBR1 or Cep55. (e) Over-
expression of CEP55-EGFP increases the percent of MBd+ cells (left; p=0.0007, n=3) 
and the percent of NBR1-negative MBds (middle; p=0.0568, n=3), presumably by 
sequestering NBR1 away from MBds in cells expressing CEP55-EGFP (right), and 
consequently preventing MBd degradation. The dotted box in right panel is enlarged (top 
right panel), and the labeling of NBR1 and CEP55-EGFP (middle and bottom right panel) 
are also presented. DAPI, DNA (blue). Bar, 5 µm. The data are presented as mean ± s.d. 
(b, c, and e).  
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Cells enriched in MBds exhibit increased reprogramming efficiency 
We next examined the functional consequences of manipulating MBd levels. We first 
tested the role of MBds during reprogramming (Yu et al., 2007; Park, et al., 2008; Chan et 
al., 2009) in cells stably expressing NBR1-specific shRNAs (shNBR1) to increase MBd 
levels over controls (shNT). MBd levels increased ~1.8-fold in dH1f cells, ~1.5-fold in 
IMR90 embryonic fibroblasts (Yu et al., 2007), and ~1.9-fold in hFib2 adult fibroblasts 
(Park, et al., 2008). Under these conditions, iPSC colony formation increased 
significantly in all three cell types depleted of NBR1: dH1f cells (up to 8.7-fold, avg. 
3.1±0.5-fold), IMR90 cells (up to 4.2-fold, avg. 3.4±0.8-fold; Fig. 2-8a, b and 
supplementary information Table. 2-S1) and adult hFib2 cells (up to 2.5-fold, avg. 
1.7±0.5-fold). Similar results were obtained with different batches of viruses, different 
combinations of reprogramming factors, and different viral delivery systems (see 
Methods). Importantly, increased reprogramming following NBR1-depletion occurred 
without significant changes in global autophagic activity (dH1f; Fig. 2-8c) or cell 
proliferation rate (shNBR1: 27.3±2.5hrs; shNT: 26.8±4.5hrs; n=6), suggesting that NBR1 
is selective for MBd degradation.  
Cancer cells enriched in MBds exhibit increased in vitro tumorigenicity  
Because MBds selectively accumulate in stem cell niches, hESCs, and iPSCs, we 
reasoned that they may also accumulate in CSCs. On the basis of Hoechst 33343 
extrusion, the side population (SP) of MCF-7 cells (Engelmann et al., 2008) was isolated. 
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These putative CSCs showed a 7-fold increase in MBd+ cells over the non-SP population 
(MP; Fig. 2-8d).  
To directly address the role of MBds in cancer cells, MKLP1-GFP-expressing HeLa 
populations with high or low percentages of MBd+ cells were isolated by FACS, and 
tested for anchorage-independent growth. Increased colony formation was observed in 
the “MBd high” versus the “MBd low” population, and colony formation increased with 
increasing MBd levels (up to 4-fold; Fig. 2-8e). An increase in colony formation was also 
observed in MBd-enriched HeLa cells (Fig. 2-8f, left) and mouse hepatocarcinoma cells 
(134-4; Fig. 2-8f, right) following NBR1-silencing. Results of all three strategies suggest 
that MBds in cancer cell subpopulations may contribute to their tumorigenic potential.  
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Figure 2-8 MBd enrichment increases reprogramming efficiency and enhances in 
vitro tumorigenicity. (a-c) Reprogramming is more efficient after MBd enrichment. 
Differentiated cells (dH1f) and embryonic fibroblasts (IMR90) are reprogrammed after 
stable expression of either NBR1-specific shRNA (shNBR1) or non-targeting shRNA 
(shNT). Emerging iPSC colonies are scored based on Tra-1-60 expression37. (a, b) Cells 
depleted of NBR1 to increase MBd levels show an increase in iPSC colony formation (a, 
dH1f: 3.1±0.5-fold, n=15, p=0.00035; IMR90: 3.4±0.8-fold, n=3, p=0.02; data are mean 
± s.e.m.) but insignificant changes in autophagic activity (c) over shNT control. (b) 
Representative plates with Tra-1-60-immunostained iPSC colonies. Immunoblot (c, top) 
and densitometry (c, bottom; percent of autophagic flux) show representative result 
(n=3); a-tubulin, loading control. (d) MCF-7 side-population (SP) cells have a 
significantly higher percentage of MBd+ cells over the non-SP population (MP; 
p=0.0015, n=3; data are mean ± s.d.). (e, f) MBd enrichment in cancer cells leads to 
increased anchorage-independent growth. MKLP1-GFP-expressing HeLa cells are 
separated into “MBd high” and “MBd low” subpopulations. An increase in the “MBd 
high” over “MBd low” ratio is associated with an increase in soft-agar colony formation 
(e). No significant difference was observed when the enrichment of MBd high 
subpopulation was less than 3-fold. More soft-agar colonies are formed when MBds are 
enriched by NBR1-depletion (shNBR1) in HeLa (f, left; p=0.0012, n=3) and mouse 134-
4 cells (f, right; p=0.0086, n=3); control, shNT. Data are mean ± s.d., and the colony 
number (e, f) is the sum of INT-violet-stained colonies from 10 random fields. 
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DISCUSSION 
We have identified new roles for MBds outside their canonical function in 
cytokinesis. This work provides the first evidence for MBd-accumulation in stem cells, 
hESCs and iPSCs in vivo and in vitro, and for dramatic MBd reduction in differentiating 
progeny of stem cells. MBds appear to function in maintaining or enhancing the 
pluripotency of stem cells and the tumorigenicity of cancer cells.  
Our findings suggest that MBd loss that accompanies stem cell differentiation is 
mediated by autophagic degradation, resulting in selective elimination of MBds in 
differentiated cells but retention in germ or stem cells. This process is intriguingly similar 
to clearance of P granule components in committed somatic cells of C. elegans, which is 
also mediated by autophagy (Zhang et al., 2009). Moreover, P granules contain molecules 
required for cell fate specification (Strome, 2005), and MBds contain stem cell markers 
(Marzesco et al., 2005, Dubreuil et al., 2007) and enhance cell fate conversion (present 
study). It is thus tempting to propose that MBds may serve as scaffolds for organizing cell 
fate determinants. Equally intriguing is the observation that essentially all cancer cells 
examined contain MBd-accumulating subpopulations, making this a common intrinsic 
property of both stem cells and cancer cells. The observation that MBd-enriched cancer 
subpopulations exhibit enhanced in vitro tumorigenicity is consistent with the CSC model 
for potentiation of tumorigenicity (Pardal et al., 2003; O'Brien et al., 2007; Visvader et 
al., 2008; Pece et al., 2010). 
Our data identify two primary mechanisms for MBd-accumulation. The first is 
asymmetric MBd inheritance by the daughter cell with the older centrosome (Fig. 2-9, 
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top). In fly testes and mouse neocortex, the old centrosome segregates to the stem cell 
during asymmetric divisions and is accompanied by increased microtubule-anchoring 
ability (Yamashita et al., 2003, 2007; Wang et al., 2009). MBd inheritance could be 
facilitated through increased anchoring of microtubules to the older centrosome, and 
increased microtubule binding to the MBd in the daughter cell with the older centrosome. 
This would be consistent with the observed MBd-accumulation in stem cells but not in 
their differentiated progeny. Despite the slower division rate of stem cells in vivo (Fuchs, 
2009), MBd-accumulation could still occur via this mechanism. However, our results also 
indicate that such asymmetry occurs in different cell types, suggesting that it may only be 
physiologically relevant in stem cells and CSCs.  
Evasion of autophagic degradation is a second mechanism for MBd-accumulation 
(Fig. 2-9, bottom). This is exemplified by the inverse relationship between MBd levels 
and autophagic activity, and by changes in MBd levels with manipulation of autophagy 
levels. MBd-accumulation can also be mediated by uncoupling receptor-mediated entry 
into the autophagy pathway, since depletion of the NBR1 autophagic receptor or over-
expression of the corresponding ligand, Cep55, increases MBd levels. In contrast, another 
known autophagic receptor, p62, does not appear to be involved in MBd clearance (Fig. 
2-7b, c, 2-S6). NBR1 and p62 can form a complex (Lamark et al., 2003; Kirkin et al., 
2009a); however, evidence suggests that they may act independently as autophagic 
receptors (Kirkin et al., 2009a). Thus, p62/NBR1 complex formation may not be a 
prerequisite for autophagic degradation. Since NBR1-silencing increases MBds to levels 
seen following inhibition of autophagy in HeLa cells (Fig. 2-6c and 2-7b), NBR1-
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mediated autophagic degradation likely represents a major pathway for selective MBd 
elimination. However, it is still possible that other autophagic receptors and MBd ligands 
may exist and contribute to MBd degradation, even though Cep55 is the sole MB ligand 
for the NBR1 receptor identified thus far (Fig. 2-7d). In our model, Cep55 and NBR1 and 
perhaps other MBd ligands and autophagy receptors, act as switches that control MBd 
fate. Ongoing proteomic analyses may identify other molecules and pathways for MBd 
degradation.  
MBd levels can be further increased in autophagy-compromised Atg5-/- MEFs when 
lysosome enzymes are inhibited (supplementary information, Fig. 2-S7), suggesting that 
other degradative pathways may contribute to MBd degradation. Chaperone-mediated 
autophagy (CMA; Majeski and Dice, 2004; Mizushima et al., 2008), which targets ~30% 
of cytosolic proteins and is upregulated upon compromised autophagy (Kaushik et al., 
2008), is a potential candidate since multiple MB proteins contain CMA-targeting motifs 
(KFERQ-like motifs; Majeski and Dice, 2004; supplementary information, Table 2-S2). 
The proteasome system is another major cellular degradation pathway (Nedelsky et al., 
2008) but it doesn’t appear to play a role in MBd degradation (supplementary 
information, Fig. 2-S8). 
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Figure 2-9 Model for MBd fate in cells. The newly-formed MBd is preferentially 
inherited by the daughter cell with the older centrosome (top panel). The inherited MBd 
(black ring) is recognized by binding of the NBR1 autophagic receptor (grey circle) with 
the MB protein Cep55 (magenta). The MBd is then encapsulated by the autophagosome 
(yellow circle), and degraded after fusion of autophagosome and lysosome (red circle) in 
differentiated cells. This pathway prevents MBd-accumulation. In contrast, stem cells 
efficiently accumulate MBds through successive divisions and evasion of NBR1-
mediated autophagy. Additionally, differentiated and stem cells possess overall high and 
low autophagic activity, respectively.  
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Other non-degradative processes may also regulate MBd levels. Even though 
elevated proliferation rate has been proposed as a factor hindering autophagic MBd 
degradation and causing MBd-accumulation in cancer and normal cells (Pohl and Jentsch, 
2009), we didn’t observe such a correlation (Fig. 2-4a). Additional work is required to 
determine if MBd-accumulation also requires selective sequestration of previously 
inherited (pre-existing) MBds, as suggested by selective accumulation of MBds in stem 
cells of the testes and lateral ventricle of the brain (Fig. 2-3a-d). Release of MBds has also 
been observed in chicken and mouse neural progenitors (Marzesco et al., 2005; Dubreuil 
et al., 2007) and in human cells (Mullins and Biesele, 1977; and Fig. 2-1g), and may be 
another, possibly minor pathway for eliminating MBds (or for intercellular signaling, 
Dubreuil et al., 2007). Finally, ongoing work is addressing whether MBds are distributed 
to both daughters of stem cells during symmetric divisions as might be expected if MBds 
are essential for stem cell function. 
In summary, our results demonstrate that MBds are more than the remnants of 
cytokinesis. Their fate is differentially controlled in different cell types and mediated by 
diverse pathways. The shared ability to accumulate MBds by stem cells and putative 
CSCs, and the striking impact on cellular phenotypes following manipulation of MBd 
levels suggest that MBds perform important cell type-specific functions that remain to be 
discovered.  
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CHAPTER III 
 
IDENTIFICATION OF CELL CYCLE PHASE-SPECIFIC INTERACTORS AND   
PHOSPHORYLATION SITES OF THE AUTOPHAGY RECEPTOR PROTEIN 
NBR1 
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INTRODUCTION 
Autophagy is a catabolic degradative process that involves the formation of a 
double-membrane structure known as the autophagosome. This structure forms around 
and encapsulates cellular cargoes, such as protein aggregates, organelles, or invading 
bacteria. Following encapsulation of cargoes, the authophagosome fuses with the 
lysosome, resulting in cargo degradation and nutrient recycling. Autophagy was first 
described as a non-selective, bulk cytoplasmic degradation system; however, with the 
identification of autophagy receptors conferring cargo specificity, the selectivity of 
autophagy is being unraveled. 
Several autophagy receptors have been identified in mammals, including: 
p62/SQSTM1, NBR1, NDP52 and optineurin (Bjorkoy et al., 2005; Pankiv et al., 2007; 
Kirkin et al., 2009a; Thurston et al., 2009; Wild et al., 2011). These receptors interact 
with both cargos and Atg8/LC3-homologues on the autophagosomal membrane, bringing 
selected substrates into close proximity with autophagy machinery. Of the known 
selective autophagy receptors, NBR1 and p62 share very similar domain structures (Fig. 
3-1) that include: a PB1 domain (PB1), a zinc finger binding domain (ZnF), an LC3-
interacting region (LIR), and an ubiquitin-associated motif (UBA). NBR1 and p62 were 
originally thought to act cooperatively based on their ability to interact through the PB1 
domain and colocalize at cytoplasmic puncta (Lamark et al., 2003; Kirkin et al., 2009a). 
In addition, both NBR1 and p62 contribute to ubiquitinated substrate removal  
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Figure 3-1 Exogenously expressed NBR1, but not p62, promotes MBd degradation. 
Upper: schematic figures of p62 and NBR1. Numbers indicate length of proteins in 
amino acids. PB1, Phox and Bem1p domain; ZnF, Zinc finger domain, CC, coiled-coil 
domain; LIR, LC3-interacting region; UBA, Ub-associated domain. The figure is adapted 
from Kirkin et al., 2009b. Lower: HeLa cells were transfected with GFP, GFP-p62, or 
GFP-NBR1 as indicated for 48hrs. Cells were fixed and immunostained for GFP, MB 
marker MKLP1, and a-tubulin, mitotic MB and cell boundary marker. MBd levels (the % 
of MBds+ cells were only quantified in cells showing GFP expression. The averaged MBd 
level for each condition was normalized against the control. MBd levels are significantly 
decreased following overexpression of NBR1 (0.7-fold, p=0.01, n=3).  
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(Kirkin et al., 2009a). However, there is evidence suggesting that NBR1 and p62 act 
independently on different substrates. For example, NBR1 and p62 degradation by 
autophagy is independent of each other (Kirkin et al., 2009a). Also, following Salmonella 
enterica invasion, p62 is required for autophagosomal engulfment of the bacteria, while 
NBR1 has no effect (Zheng et al., 2009). Moreover, my findings provide evidence that 
NBR1, not p62, is the cargo receptor for the post-mitotic midbody (midbody derivative, 
MB
d
) through the MB protein Cep55. Depletion of NBR1 impeded MB
d
 autophagosome 
encapsulation, thereby increasing MB
d
 levels (Fig. 2-7b and 2-S5), whereas NBR1 
overexpression promoted MBd clearance (Fig. 3-1). By contrast, loss of p62 or p62 
overexpression had no detectable effect on MB
d levels (Fig. 2-7b, c, 2-S6, and 3-1) or 
NBR1 recruitment to MB
d
s (Fig. 2-7a, bottom). Thus NBR1-mediated MBd degradation 
is an autophagy pathway that does not require p62.  
MBd degradation appears to be distinct from the degradation of protein aggregates. 
The MBd resembles protein aggregates and/or inclusions because of its large size. 
However, we found MBd degradation was not promoted by the autophagy-linked FYVE 
protein Alfy, a key factor involved in aggregate degradation (Fig. 3-2). Therefore, NBR1-
mediated autophagic degradation of MB
d
s likely represents a unique form of selective 
autophagy.  
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Figure 3-2 Alfy overexpression does not promote MBd degradation. Upper: 
schematic figure of Alfy showing the location of its BEACH domain, WD-40 repeats, 
and FYVE domain, which mediates its interaction with p62, Atg5, PI3P, respectively. 
Alfy truncations containing WD-40 repeats and FYVE domain (aa 2981-3526) are 
capable of promoting aggregate clearance when overexpressed (Filimonenko et al., 2010). 
Numbers indicate amino acids. The figure is adapted from Filimonenko at al., 2010. 
Lower: HeLa cells were transfected with Tomato or different Alfy truncations as 
indicated for 48 hours. Cells were fixed and immunostained for MBd quantification as 
described above. The average of two independent experiments is shown. Error bars 
represent standard deviations.  
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Based on this, we aim to identify additional NBR1-mediated degradation pathway 
members and the spatiotemporal mechanism involved in NBR1-mediated MB
d
 
degradation. In this chapter, we present the first proteomics study on the NBR1-
interaction network. Our results reveal several new potential cofactors and MB
d
 
substrates for NBR1, as well as modification events that may regulate NBR1 substrate 
recognition. Together, our results reinforce a primary role for NBR1 in MB
d
 degradation. 
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RESULTS AND DISCUSSION 
Proteome analysis of NBR1-containing protein complexes reveals potential players 
involved in MBd degradation 
To identify additional MB proteins that serve as recognition molecules for NBR1, as 
well as other proteins that cooperate with NBR1 to mediate MBd degradation, we 
performed mass spectrometry analyses to identify NBR1 interactions. To purify NBR1-
interacting proteins, a fluorescent protein-based tandem affinity purification tag (MAP) 
that contains His8, SBP, Flag, and mVenus-tags was used (Ma et al., 2012). The mVenus 
tag allowed us to confirm that MAP-tagged NBR1, like endogenous NBR1, localizes to 
cytosolic puncta structures, and can accumulate in the lysosome (data not shown). We 
purified NBR1-MAP complexes from asynchronous cells or mitotic cells, and then the 
purified complexes were digested and subjected to two-dimensional liquid-
chromatography-tandem mass-spectrometry (2D-LC-MS/MS, MudPIT, in collaboration 
with Dr. Kathleen Gould’s group).  
LC-MS/MS of NBR1-MAP purifications identified a large number of potential 
NBR1 interacting partners that are specifically enriched in asynchronous cells (Table 3-1) 
or mitotic cells. In addition, we confirmed known interactions between NBR1 and p62, 
ubiquitin, MAP1B, and Cep55 (chapter II; Kirkin et al., 2009a; Marchbank et al., 2012), 
suggesting that our LC-MS/MS of NBR1-MAP interactions was robust. To search for 
factors involved in NBR1-mediated MBd degradation, we focused on the proteins that are 
frequently detected from asynchronous cells (n=158, identified by at least 2 unique  
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peptides and > 8 total spectral counts), given that MBd degradation is a post-mitotic event. 
We compared our identified NBR1 interaction network with reported autophagy-relevant 
protein networks (networks composed of 409 high-confidence candidate interaction 
proteins, Behrends et al., 2010). This comparison revealed an overlap of 17 proteins 
(10.7% of NBR1-binding proteins present in interphase). 
Several of these proteins, like NBR1, are known to bind multiple Atg8/LC3 
homologues (Behrends et al., 2010), thus are particularly interesting as they could 
potentially link the MBd to the autophagosome membrane with NBR1. Among them, 
RB1CC1, CLTC, and KEAP1 have been implicated in autophagy. RB1CC1 contributes 
to autophagosome formation through stabilizing the ULK1 kinase complex, while CLTC 
provides needed membrane from the trans-Golgi network for autophagosome formation 
(Hara et al., 2008; Guo et al., 2012). KEAP1 is localized to ubiquitinated protein 
aggregates and appears to facilitate aggregate degradation (Fan et al., 2010). Although 
the function is unknown, proteins NIPSANP1 and GBAS have domains similar to the t-
SNARE protein SNAP25, suggesting their potential involvement in vesicle transport and 
fusion (Behrends et al., 2010). Because CLTC, KEAP1, and NIPSNAP1 were detected in 
the mitotic MB proteome (see below, Skop et al., 2004), they are considered as our 
primary candidates in mediating MBd degradation. Besides these autophagy-related 
proteins, 16 additional candidates (10.1% NBR1-binding proteins) are also associated 
with intracellular transport pathways, such as GRP78 and Cep57 (Huang et al., 2009a and 
2009b). Future analyses are required to validate their participation in MBd degradation. 
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So far, the MB protein Cep55 is the only known MB
d
-localized autophagy substrate 
that links the MB
d
 to autophagy degradation (Fig. 2-7a, d, e). To determine if other MB 
proteins in addition to Cep55 could be targets for NBR1, we compared the NBR1 
interaction network with the mitotic MB proteome (Skop et al., 2004). Strikingly, we 
found that 28 of the NBR1-binding proteins (17.7% of the 158 interactions) were also 
detected in the mitotic MB proteome (Table 3-2), including known MB proteins PLK1, 
MYH9, FLNA, and KIF11 (Wei and Adelstein, 2000; Tsvetkov et al., 2003; Ma et al., 
2010; Mondal et al., 2012). PLK1 and MYH9 remain on the MBd (Fig. 3-3; Hu et al., 
2012), suggesting that they may function as additional substrates for NBR1 to mediate 
MBd degradation. These proteins may act in concert with Cep55 to recruit NBR1 and/or 
other potential autophagy-related members to the MB, thereby creating more docking 
sites for efficient elongation and fusion of the autophagosome precursors around the 
MBds. Overexpression experiments of PLK1 or MYH9 could help to confirm this 
hypothesis as their overexpression may sequester NBR1 away from the MB thus resulting 
in increased MBd level. 
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Figure 3-3 Plk1 and Myh9 are localized to both mitotic MB and the MBd. Single-
plane confocal images showing localization of Plk1 (Upper) and Myh9 (Lower) on both 
mitotic MB and the MBd. Mklp1, MB marker; Aurora B and α -tubulin, mitotic MB 
marker. 
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Phosphorylation site mapping of NBR1 reveals potential regulatory events for 
NBR1’s function in autophagy 
The integrity of the mitotic MB is essential for proper cytokinesis to occur as it 
serves as a platform to localize factors and orchestrates events required for faithful 
abscission (reviewed in Hurley and Hanson 2010; Lekomtsev et al., 2012). Therefore, the  
NBR1-mediated MBd degradation by autophagy is an event that must be prohibited 
before (or activated after) abscission. Emerging data have suggested roles for post-
translational modifications, particularly phosphorylation events, in regulating selective 
autophagy (Matsumoto et al., 2011; Wild et al., 2011). Interestingly, we found that NBR1 
is phosphorylated in a cell cycle-dependent manner. It is hyperphosphorylated during 
mitosis, but becomes dephosphorylated after abscission has completed, and remains 
dephosphorylated throughout interphase (Fig. 3-4). Based on this observation, I propose 
that NBR1 phosphorylation may serve as a regulatory strategy to limit autophagic cargo 
recognition and untimely MB degradation.  
We performed mass spectrometry analyses to map NBR1’s cell cycle stage-
specific phosphorylation sites. LC-MS/MS of NBR1-MAP purifications identified a 
number of NBR1 phosphorylation sites that occur specifically in mitotic or asynchronous 
cells (Fig. 3-5). We found that several phosphorylation sites are located nearby or within 
domains that have been implicated for NBR1’s function in autophagy: the LC3-
interaction region (LIR), the LC3-interaction region 2 (LIR2) and the juxta-ubiquitin 
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Figure 3-4 NBR1 is hyperphosphorylated in mitosis. a: Cell lysates from 
asynchronous (Asyn), S phase, and mitotic NBR1-MAP expressing U2OS were treated 
with λ-phosphatase (PPase) or both λ-PPase and PPase inhibitor and immunoblotted with 
an anti-NBR1 antibody. S phase and mitotic cells were prepared by aphidicolin and 
nocodozole treatment, respectively. b: Cell lysates from asynchronous or mitotic cells 
were prepared as in a. To prepare lysates from post-abscission cells, mitotic cells were 
first collected by shake-off and then re-plated. Four hours later, when most cells already 
completed abscission, cell lysates were collected for immunoblotting. NBR1-MAP was 
detected by either anti-NBR1 or anti-GFP antibodies. 
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associated domain (JUBA). NBR1 has two LIR domains, both of which can mediate 
NBR1 binding to LC3 in vitro (Kirkin et al., 2009a). The JUBA region is a novel region 
preceding the UBA domain and mediates membrane interaction (Mardakheh et al., 2010). 
Together with the UBA domain, these three regions contribute to the autophagic 
degradation of ubiquitinated aggregates and peroxisomes (Kirkin et al., 2009a; Deosaran 
et al., 2012). The phosphorylation sites within these domains likely act as molecular 
switches that control NBR1 function, as illustrated by other autophagy receptors. For 
instance, the autophagy receptor required for the clearance of cytosolic Salmonella, 
Optineurin, displays higher binding affinity to LC3 and promotes autophagy of the 
bacteria when a residue adjacent to its LC3-interacting motif is phosphorylated (Wild et 
al., 2011). Accordingly, future experiments can be designed to test if the phosphorylation 
sites enriched in mitosis within these domains function as negative regulators for NBR1’s 
function in autophagy, and furthermore if the phosphorylation sites enriched in interphase 
act in opposite manner as positive regulators for NBR1’s function in autophagy. 
 
 
 
 
 
 
 
 
63
                 
64
 
CONCLUSIONS 
In this chapter, we reported the first proteomics study on NBR1. Through 
comparative proteomics and gene ontology analysis, we identified a list of proteins that 
are potentially involved in NBR1-mediated MBd degradation (Table 3-1). We also 
identified a number of phosphorylation sites in NBR1 domains critical for autophagy 
function (Fig. 3-5). In addition, our findings provided a preliminary understanding of the 
selectivity of different autophagy pathways (NBR1 vs. p62), based on the extensive 
difference in associated proteins isolated (Fig. 3-6). Because the role of autophagy 
receptors in selective autophagy is not well understood, and the exact molecular 
mechanisms underpinning cargo recognition are still obscure, these initial interaction and 
phosphorylation profiles of NBR1 can be very useful for the future autophagy research.  
Our NBR1 profiles are also critical for understanding MBd function in stem and cancer 
cells and have implications for cancer research, given the potential importance of MBd 
accumulation (chapter II). As more factors and detailed mechanisms modulating MBd 
accumulation are revealed, the role(s) of MBds can be addressed more sophisticatedly and 
precisely. Ultimately, strategies that directly and selectively target MBds in cancer cells 
can be developed without affecting normal cells in the body. 
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Figure 3-6 Overlap of interacting proteins found between NBR1 and p62 by LC-
MS/MS. The list of p62-interacting proteins is from Behrends et al., 2010. All proteins 
used for comparison were detected with at least 2 unique peptides and 8 total spectral 
counts.  
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CHAPTER IV 
 
General Discussion 
 
The midbody (MB), a transient organelle formed between two daughter cells 
during cell division, is well known for its role in abscission, the last step of cytokinesis. 
Chapter II outlines the work that myself and colleagues in the Doxsey laboratory 
performed to determine the fate and function of MBds. We found that MBds are degraded 
soon after abscission in normal dividing cells but can accumulate in stem and cancer cells 
through evasion of NBR1-mediated autophagic degradation. Cells that were enriched 
with MBds through depletion of NBR1 displayed enhanced anchorage-independent 
growth and cellular reprogramming. In chapter III, we identified additional MBd 
substrates for NBR1 and showed that MBd degradation can only be promoted by NBR1, 
but not other autophagy factors required for aggregate degradation, like p62 or Alfy. Our 
proteomics analysis also reveled several potential cofactors as well as post-translational 
modification events to be involved in NBR1-mediated autophagy. In summary, my thesis 
research has manifested a role of selective autophagy in regulating MBd fate and 
function. My results suggest that NBR1-mediated MBd degradation is a distinct form of 
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selective autophagy, and also propose a role for MBds in regulating cell fate 
determination. 
p62, a receptor protein that targets ubiquitinated proteins and aggregates for 
autophagosomal degradation, was previously shown to be involved in MBd clearance 
(Pohl and Jentsch, 2009). Our results, however, suggested that MBd degradation is not 
mediated by p62, but by the structurally related receptor NBR1. siRNA-mediated p62 
silencing using the published siRNA sequence (Pohl and Jentsch, 2009) did not show any 
detectable effects on MBd levels in two different cell lines (HeLa and U2OS; Fig. 2-7b 
and 2-S6). Moreover, we found no changes in MBd levels in cells where p62 was 
completely lost by genetic deletion (Fig. 2-7c) or in cells where p62 was ectopically 
expressed, in contrast to NBR1-overexpressed cells (Fig. 3-1). Furthermore, our mass 
spectrometry analysis of NBR1-containing complexes identified more than twenty MB-
localized proteins, suggesting them as MBd substrates for NBR1. However, only two of 
the high-confidence p62 interactiors are known to localize to the MB (Skop et al., 2004; 
Behrends et al., 2010). These results reinforce that NBR1 and p62 can function in 
different forms of selective autophagy (Kirkin et al., 2009a; Itakura et al., 2011), and also 
demonstrate that p62 is not a likely receptor for MBd autophagic degradation, although it 
is localized to the mitotic MB at the time of MB ubiquitination (Pohl and Jentsch, 2009). 
Given that Pohl and Jentsch appeared to analyze both mitotic MBs and MBds, whereas 
we focused solely on MBds (see MATERIALS AND METHODS), we have been 
wondering if the discrepancy between studies is due to the difference in the methods of 
MBd quantification. A caveat with quantifying both mitotic MBs and MBds is that any 
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increase in mitotic progression or delay will also affect MBd levels. Interestingly, the 
transition from mitosis to interphase is slower in cells that have reduced p62 (Linares et 
al., 2011). In addition to this, a difference in the efficiency of protein depletion could also 
be a possible explanation for our discrepant results. We feel this later possibility is less 
likely as p62 depletion was ~95% (Fig. 2-7b) and MBd analysis was only done in cells 
negative for p62 immunofluorescence. However, we could not rule out the possibility that 
residual p62 that was below the detection limit of immunofluorescence microscopy still 
mediated MBd degradation. Future studies that utilize the same MBd quantification 
method as well as other known p62 substrates as experimental controls to better 
demonstrate the loss of p62 will hopefully clarify the role of p62 in MBd degradation. 
Additionally, since autophagy receptors function to link selective cargoes to 
autophagosomes (Kim et al., 2008; Kirkin et al., 2009a; Thurston et al., 2009; Ogawa et 
al., 2011) and loss of NBR1 leads to a decrease in autophagosome localization of the 
MBd (Fig. 2-S5). To demonstrate a role of p62 in acting as an autophagy receptor for the 
MBd, it will be necessary to determine if p62 loss also causes a deficit in the 
autophagosomal encapsulation of MBds. 
A number of autophagy receptors and adaptors have been identified for selective 
autophagy. In several cases, autophagy receptors and adaptors act cooperatively to target 
the designated cargo to Atg8/LC3-positive autophagosomal compartments. NBR1 is so 
far the only known receptor with substantial function in MBd degradation, other 
receptors/adaptors, yet to be tested, may also function in MBd removal. A recent 
proteomics study revealed a number of proteins to have high-confidence interactions with 
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the Atg8/LC3 family homologues, suggesting roles for these proteins in autophagy 
(Behrends et al., 2010). As some of these proteins (e.g., KEAP1, NIPSNAP1, GBAS, 
CLTC, and RBICC1) were shown to interact with NBR1 (Chapter III), it is tempting to 
speculate that these proteins act in concert with NBR1 to mediate MBd degradation 
through autophagosome recruitment. Other Atg8 homologue-interacting proteins 
(identified in Behrends et al., 2010) that do not appear to bind NBR1 could be involved in 
MBd degradation in an NBR1-independent manner through binding to other yet 
unidentified receptors. Future candidate characterization will delineate the mechanisms 
responsible for MBd degradation. 
The trigger that initiates MBd degradation at the right time and place is currently 
unknown. Undoubtedly the cell would have to maintain the MB structure during 
cytokinesis, as the integrity of the mitotic MB is essential for faithful cell separation (Hu 
et al., 2012; Joseph et al., 2012). Given that NBR1 is localized to both mitotic MBs and 
MBds, NBR1 may be the trigger that recognizes whether a MB is mitotic or a derivative. 
Along these lines, NBR1 displays mitotic specific phosphorylation (Fig. 3-4). Therefore, 
several possibilities arise from our NBR1 phosphorylation mapping results (Fig. 3-5). For 
example, it would be interesting to examine if the mitosis-specific phosphorylation sites 
near the LC3-binding region of NBR1 (T743, T749, and T756) serve as an inhibitory 
regulation to prevent NBR1 from binding to LC3, thereby suspending autophagosomal 
encapsulation of the MB until abscission is completed. In support of this idea, T743 is a 
predicted phosphorylation site for PLK1, a kinase with roles in several steps of mitosis, 
including the formation and maintenance of the MB during cytokinesis (Hu et al., 2012). 
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Conversely, the NBR1 phosphorylation sites near the LC3-binding regions that are 
enriched in asynchronous cells may positively regulate MBd degradation. Of these sites, 
T658 and T673 are particularly interesting, in that these two sites are predicted binding 
sites for 14-3-3 proteins. When associated with the mitotic MB, 14-3-3 leads to abnormal 
MB disintegration before abscission (Joseph et al., 2012). Given that protein 
phosphorylation has been implicated in the regulation of autophagy receptors, and those 
modifications occur within the domains commonly shared among autophagy receptors 
(Matsumoto et al., 2011; Wild et al., 2011), a similar mechanism may exist to regulate 
NBR1 activity.  
 In addition to post-translational modifications of the receptor, specific 
modifications in MB proteins could also trigger degradation. During the final stages of 
cytokinesis, it is known that MB proteins are ubiquitinated (Pohl and Jentsch, 2008). 
Since autophagy receptors (e.g., p62 and NBR1) localize to the MB, ubiquitin 
modification has been suggested to serve as an initial trigger for autophagic degradation 
of the MBd (Pohl and Jentsch, 2009). However, this potential mechanism for MBd 
degradation initiation has yet to be conclusively tested. Interestingly, Cep55 in NBR1 
immunoprecipitates does not appear to have a molecular weight shift for ubiquitin 
modification in Western blotting analysis (Fig. 2-7d and 2-S9), suggesting that the 
interaction between NBR1 and Cep55 does not require ubiquitin modification of Cep55. 
Furthermore, although the MB protein MKLP1 is ubiquitinated during cytokinesis (Pohl 
and Jentsch, 2008), we were not able to detect MKLP1 in NBR1-immunoprecipates, 
demonstrating that ubiquitination is not sufficient to trigger NBR1-mediated MBd 
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degradation. Due to NBR1’s specificity for non-ubiquitinated Cep55 and its p62-
independent role in MBd clearance, I propose that other modifications beside 
ubiquitination are used for regulating NBR1-mediated MBd degradation. Further domain 
analysis of NBR1 and Cep55 would likely provide more information on this subject with 
regard to the post-translation modifications within the domains required for their 
interaction. As many MB-localized proteins are identified in NBR1-containing 
complexes, it would also be interesting to see if a modification common to all of these 
proteins is involved in mediating their binding to NBR1.  
 A question that I am always interested in is how MBds in stem cells and cancer 
cells escape recognition by autophagic machinery. Our results suggest MBd accumulation 
in these cell types is dictated partly by the level of autophagic activity because these 
MBd-high cells possess lower basal autophagic activity compared to MBd-low cells and 
MBd levels are reduced upon autophagy induction (Fig. 2-6). In support of this idea, 
constitutive activation of the PI3K-Akt-mTOR signaling pathway, which negatively 
regulates basal autophagy, often occurs in cancer cells (reviewed in Menon & Manning 
2008; Laplante & Sabatini, 2012). Additionally, MBd accumulation is controlled by the 
amount of autophagy receptor, since exogenous NBR1 can further promote MBd 
degradation in autophagy-component cells (Fig. 3-1). The amount of a given protein is 
determined by the balance between its synthesis and degradation. NBR1 degradation is 
mediated by autophagy (Kirkin et al., 2009a), therefore NBR1 levels could be higher in 
autophagy-low stem and cancer cells, compared to autophagy-high normal differentiated 
cells. However, the synthesis of NBR1 have not been examined in cells with different 
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differentiation status. It thus will be interesting to test if stem and cancer cells regulate 
NBR1 synthesis differently compared to normal dividing cells. It’s also possible that 
cancer and stem cells have distinct NBR1 or MBd modifications that prohibit the MBd 
from degradation.  
In contrast to the idea that the MBd fate is passively determined by the cellular 
autophagy activity, the MBd itself could regulate its own degradation through recruiting 
or releasing factors crucial for autophagy induction. Such factors could be mediators 
involved in the PI3K-Akt-mTOR signaling cascade that negatively regulates autophagy 
(Fig. 1-1; reviewed in Yang & Klionsky, 2010). Active mTOR associates with the MB 
during cytokinesis as indicated by its serine2481 autophosphorylation form (Peterson et 
al., 2000; Copp et al., 2009; Vazquez-Martin et al., 2009 and 2012; Soliman et al., 2010). 
Moreover, the active form of the mTORC1 upstream effector, Akt, is also localized to the 
MB (Mao et al., 2012; A. Purohit and S. Doxsey, unpublished results). Furthermore, 
MB(d) protein Cep55 is known to interact with the PI3K complex and enhances the 
kinase’s activity (Chen et al., 2007). Collectively, these results indicate active PI3K-Akt-
mTOR signaling on the MB and also suggest a possibility of the MBd in the control of it 
own fate.  
 Perhaps the most intriguing question raised by this thesis study is how MBds 
contribute to tumorigenicity and pluripotency. Despite limited information on MBd 
composition, several MBd proteins have been individually associated with stem cell 
maintenance and cancer progression. For instance, the expression of MgcRacGAP is 
required for stem cell self-renewal and is declined during differentiation (O'Brien et al., 
73
2010). Similarly, elevated expression of Cep55 or PLK1 has been found in various 
tumors and is associated with tumorigenicity (Holtrich et al., 1994; Takai et al., 2005; 
Chen et al., 2007; Inoda et al., 2009). These results together with the finding that stem 
cell marker CD133 associates with MBds (Fig. 2-2d and 2-S2) suggest a scaffolding role 
for MBds in organizing cell fate determinants. More specifically, given that Cep55 
promotes tumorigenicity by enhancing PI3K kinase activity and signaling, and that 
CD133 represses cell differentiation through p38 MAPK activation (Chen et al., 2007; 
Takenobu et al., 2011), it is tempting to speculate that MBds may serve as a hub to 
orchestrate various signaling pathways required for maintaining tumorigenicity and 
pluripotency. Further studies to determine the MBd proteome will provide more 
information on associated signaling molecules. Certainly, to establish a role for the MBd 
in serving as a signaling hub, investigations are needed to determine if the MBd 
localization of aforementioned signaling molecules is essential for their function.  
Autophagy is an essential cell makeover process used during mammalian 
developmental stages (Cecconi and Levine et al., 2008; Mizushima and Levine, et al., 
2010). At the cellular level, autophagy induction along with cell differentiation has been 
observed in several types of stem cells, including embryonic stem cells and adult stem 
cells (Fig. 2-6g; Vazquez et al., 2012; Zhang et al., 2012). Although the mechanisms by 
which autophagy participates in these processes are not clear, it is possible that autophagy 
influences cell fate by removing cell fate molecules and organelles, a hypothesis that is 
supported by our studies. In line with this idea, autophagic degradation of the oncoprotein 
PML-RARa is required for poorly-differentiated leukemia cells to differentiate (Isakson 
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et al., 2010; Wang et al., 2011). Other molecules known to control cell fate decisions, 
such as Dishevelled in Wnt signaling, have also been identified as targets of selective 
autophagy (Marson et al., 2008; Gao et al., 2010). Autophagy could therefore act as a 
transcription-independent mechanism in regulating cell differentiation. A global 
characterization of autophagy receptors and their substrates during stem cell 
differentiation and induced pluripotency will provide invaluable information to construct 
a mechanism for the role of autophagy in cell differentiation.  
Several alternative explanations for MBd accumulation and function remain 
possible at this stage, as we haven’t been able to determine MBd function by directly 
removing the MBd. Given that PI3K protein level can be variable from cell to cell (Yuan 
et al., 2011), it is possible that autophagy is heterogeneous in a given cell population and 
that MBd accumulation simply reflects the heterogeneity of autophagy. Alternatively, 
since autophagy is required for the homeostasis of various proteins and organelles under 
basal condition and since several selective autophagy pathways exist, it is not 
unreasonable to speculate that some selective autophagy pathways are more favorable 
than others by the cell under low autophagy condition. According to these ideas, the 
effects we observed from MBd enrichment represent simply the functions of other 
autophagy substrates or the importance of their homeostasis. To address these concerns, 
we could ask if depletion of other known autophagy substrates would totally abolish the 
effects of MBd enrichment on cellular reprogramming and tumorigenicity. We could also 
examine if a block in NBR1-mediated autophagy expedites other selective autophagy 
pathways, such as the degradation of mitochondria. However, since the identity and 
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function of autophagy substrates are largely unknown, strategies that attack MBd function 
without compromising autophagy are inevitable and essential in order to uncouple the 
effects of MBd accumulation from general autophagy. As discussed above, investigation 
of a unique molecular trigger for MBd degradation would likely enable the development 
of methods that specifically manipulate MBd fate during cell fate changes. Meanwhile, 
exploring signaling pathways at the MBd would hopefully shed light on the role of MBds 
in stem and cancer cells.    
In conclusion, this thesis delineates the molecular mechanism for receptor-
mediated autophagic degradation of the post-mitotic midbody. Not only did I identify the 
MBd as a cargo for the autophagy receptor NBR1, but also I provided the mechanism for 
how the MBd is targeted by autophagy. I also presented evidence identifying the 
mechanism for MBd accumulation and the functional consequences of MBd accumulation 
in cells with differentiating capabilities. In addition, these findings offer initial 
understanding of the interplay between selective autophagy and cell differentiation.  
Although the exact role of MBds has yet to be determined, this work certainly opens up 
many new avenues for future investigation.  
76
                                
 
Supplementary Figure 2-S1 Different-aged centrosomes in dividing cells show 
differential labeling for the components and modification of centrosomes. (a) 
Older/more mature centrosome retains the brighter CETN1-GFP signal throughout the 
mitotic cell cycle. Left to right: metaphase, anaphase, telophase and cytokinesis. (b) The 
centrosome pairs in representative mitotic cells show differential labeling of centriolin 
(top panel, green), hCenexin1 (bottom panel, green) and glutamylated tubulin (GT335; 
bottom panel, red). Centriolin and hCenexin1 are markers for centriole maturation, and 
glutamylated tubulin for tubulin modification at centrioles, respectively. Centrosomes are 
labeled by human autoimmune antibody 5051 (top panel, red). DAPI stains DNA (blue). 
Bar, 5 µm. 
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Supplementary Figure 2-S2 Multiple planes of confocal images demonstrate that the 
MBd (asterisk) in the ventricle-facing daughter of the dividing neural progenitor is 
intracellular (also shown in Fig. 2-3d). CD133, MB/MBd marker (green); Na-K-ATPase, 
cell-border marker (red); DRAQ5, DNA (blue); Bar, 5 µm. 
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Supplementary Figure 2-S3 Organelles respond to digitonin treatment as expected. 
(a, b) Membranous organelles are not disrupted during digitonin-mediated 
permeabilization in FPP assays. (a) hRPE-1 cells expressing Mito-EYFP to label 
mitochondria, and GAPDH-dsRed to mark cytoplasm, are pre-incubated in KHM buffer 
(110 mM potassium acetate, 20 mM HEPES, 2 mM MgCl2), and then treated either with 
0.2% TX-100 (top panel) or with 25 µM digitonin (bottom panel). TX-100 releases both 
GAPDH and Mito-EYFP from cells, whereas digitonin releases only GAPDH and does 
not disrupt mitochondrial integrity as shown by the retention of Mito-EYFP in the 
presence of Proteinase K. (b) hRPE-1 cells expressing MannII-GFP-4C, a Golgi complex 
marker (top panel), or SKL-RFP, a peroxisome marker (bottom panel), are treated with 
digitonin followed by proteinase K digestion as in (a). The fluorescent proteins in Golgi 
complex and peroxisomes are resistant to proteinase K digestion after digitonin-mediated 
permeablization, showing that the Golgi complex and peroxisomes are intact. Other 
organelles were also examined to ensure their integrity. Similar results were observed in 
HeLa cells. Bar, 5 µm. 
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Supplementary Figure 2-S4 Effects of lysosomal inhibition. (a) Lysosomal activity is 
visualized by fluorescent DQ-BSA. DQ-BSA substrates fluoresce when degraded in 
lysosomes (left, untreated) but not when lysosomal enzymes are blocked (right panels), 
confirming function of inhibitors. Bar, 20 µm. (b) Use of p62, another protein degraded 
by autophagy, as an indicator of autophagic flux confirms LC3-II results (Fig. 2-6d). I, 
inhibited by lysosomal inhibitors as in Fig. 2-6d. U, uninhibited. Actin, loading control. 
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Supplementary Figure 2-S5 NBR1 depletion impedes autophagosome capturing of 
MBds. HeLa cells were transfected with siRNA against Lamin or NBR1 as indicated for 
24 hours before bafilomycin A1 was added to block the fusion of autophagosomes with 
lysosomes. Twenty-two hours after bafilomycin A1 treatment, cells were fixed and 
immunostained for autophagosome marker LC3, midbody marker MKLP1, and a-tubulin, 
mitotic MB and cell boundary marker. The percent of MBds in autophagosomes is 
evidently decreased following NBR1 depletion. The average of two independent 
experiments is shown. Error bars represent standard deviations.  
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                                               Supplementary Figure 2-S6 
  
                                   
                                
Supplementary Figure 2-S6 p62 depletion does not affect MBds in U2OS cells. U2OS 
cells were transfected with siRNA against Lamin or p62 as indicated for 48 hours. Cells 
were then fixed and immunostained for p62, midbody marker MKLP1, and a-tubulin, 
mitotic MB and cell boundary marker. In cells transfected with p62 siRNA, only cells 
negative for p62 immunofluorescence were analyzed. MBd levels (percent of MBd-
containing cells) are not affected by p62 depletion. The average of two independent 
experiments is shown. Error bars represent standard deviations.  
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                                          Supplementary Figure 2-S7    
 
                                        
Supplementary Figure 2-S7 An unidentified lysosomal degradation pathway 
compensates for autophagy deficiency. Lysosomal inhibitor E64d/PepA treatments 
further increase the percent of MBd+ cells in atg5 knockout cells where autophagy is 
deficient, suggesting a yet identified lysosomal degradation pathway compensates for 
autophagy deficiency (p=0.0099, n=3). 
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Supplementary Figure 2-S8 The proteasome does not play a role in MBd 
degradation. (a) Ubiquitinated protein levels, assessed by anti-ubiquitin antibody, 
increase in cells treated with proteasome inhibitors (MG132, lactacystin) as indicated, 
confirming proteasome inhibition. (b) Proteasome inhibition has no significant effect on 
MBd degradation in hRPE-1 cells compared with the lysosomal inhibitor chloroquine. It 
only slightly slows the process of MBd clearance, as control cells have removed most 
MBds by 19 hours. They reenter mitosis and begin to make additional MBds from 19-25 
hours. Assays were performed by collecting mitotic cells after mitotic shake-off and 
treating cells with drugs 1 hour after re-plating, when most cells were in cytokinesis. This 
is to avoid arresting cells in mitosis and thus blocking MB formation. MBd levels (the 
percent of MBd+ cells) are determined as described above. 
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Supplementary Figure 2-S9 Full scan data of immunoblots in Fig. 2-7d.  
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MATERIALS AND METHODS  
Chapter II: 
Cell lines. hESC and iPSC lines include H1 (WA01), H9 (WA09), H1-OGN (Oct4-EGFP 
knock-in H1, Zwaka and Thomson, 2003), and dH1f-iPS (Park, et al., 2008), which is 
reprogrammed from dH1f cells differentiated from H1-OGN (HSCI at Children’s 
Hospital Boston). Differentiated lines include hRPE-1 (Clontech), MCF-10A, adult 
human fibroblasts (PCS-201-012, ATCC), hFib2 (Zwaka and Thomson, 2003), IMR90 
(CCL-186, ATCC), ex vivo C57BL/6 MEFs, GFP-LC3-expressing Atg5-/- and Atg5+/+ 
MEFs (Kuma et al., 2004), and p62-/- and p62+/+ MEFs (Komatsu et al., 2007). Cancer 
cell lines include DLD-1, HeLa, NCC-IT, PC-3, U2OS, SAOS-2, 134-4, MCF-7, MCF-
10AT, and MCF-10CA1a. Mouse skeletal muscle progenitors (SMPs; Conboy et al., 
2010) and in vitro activated T cells were isolated and stimulated following standard 
protocols. Cells were used within 4 (primary cultures) or 10 (established cell lines, 
hESCs, and iPSCs) passages. Cells expressing MKLP1-GFP, monomeric RFP and 
CETN1-GFP were created in the present study or in Piel et al., 2000. 
Immunofluorescence and Immunohistochemistry. Immunofluorescence was carried 
out as described (Gromley et al., 2005; Marzesco et al., 2005; Xu et al., 2010). To label 
lysosomes and autophagosomes, cells were permeabilized with 0.05% saponin in 
blocking buffer (10% goat serum/PBS). Preparations for immunohistochemistry were 
fixed with 4% paraformaldehyde/0.5% glutaraldehyde via perfusion. Testes were 
processed and stained following 2-4hr post-fixation with 4% paraformaldehyde. MB-
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derived rings between spermatocyte syncytia (Greenbaum et al., 2007) were observed if 
stained longer. Images were taken on a Zeiss Axioskop 2 microscope, a Zeiss Axiovert 
200 microscope with PerkinElmer UltraView LAS spinning disc, or an Olympus BX-51 
microscope. Images were processed and analyzed with MetaMorph (Molecular Devices) 
and Imaris (Bitplane Inc.).  
Electron Microscopy. Conventional EM: Mouse tissue, fixed with 5% glutaraldehyde in 
50 mM sodium cacodylate buffer (pH=7.4) for 30 min via perfusion, was diced into 1-
mm cubes for 1-hr post-fixation at 4°C. Cubes were washed with cacodylate buffer, 
stained and embedded in Spi-pon/Araldite, and sectioned at 70-500 nm before staining 
with 25% uranyl acetate and Reynold’s lead citrate. Images were taken on a Philips 
CM12 electron microscope with an Erlangshen CCD Camera (Gatan).  
Immunogold EM: MCF-7 cells on coverslips were prepermeabilized for 60 sec with 
preperm buffer (80 mM PIPES, pH6.8, 0.5 mM EGTA, 1 mM MgCl, 0.5% Triton X-
100), fixed with 4% paraformaldehyde for 10 min, labeled for MKLP1 for 1 hour, 
processed as described (Mitchison, et al., 1986) using 12-nm gold-conjugated goat anti-
rabbit IgG (Jackson ImmunoResearch) and embedded in Spi-pon/Araldite. 80-nm 
sections were cut, stained and viewed as above.  
Time-lapse imaging. CETN1-GFP-expressing lines were grown on 35-mm MatTek 
dishes (MatTek Corp.) or coverslips before imaging (Gromley et al., 2005). H9 hESCs 
were seeded on matrigel-coated dishes overnight, then transduced with CETN1-GFP, and 
grown for >72 hours in complete mTeSR1 medium (Stemcell Technologies). The 
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transduced cells were imaged every 15 min in phenol red-free D-MEM/F12 medium 
(Invitrogen) with mTeSR1 supplement and 10 mM HEPES, and stained to confirm MBd 
inheritance. Duplicate dishes of transduced cells were stained for stem-cell markers to 
ensure cell quality.  
MBd quantification. Quantification was based on the markers that: 1) labeled both 
mitotic MBs and MBds (MKLP1, mgcRACGAP, or Cep55); 2) labeled MBs differently 
than MBds (a-tubulin or Aurora B); 3) defined cell boundaries (a-tubulin or ZO-1). 
Because Cep55, MKLP1, and mgcRACGAP also label centrioles and spindle midzones, 
cells were co-stained with centrosome antibody (e.g. 5051), and a size threshold for 
MB/MBds (1 µm) was introduced to exclude non-MBd structures. Structures with MB-
specific or non-MB/MBd labeling were excluded from MBd counts. Cell counts: For 
hESCs, 5-11 colonies were imaged from triplicates in each experiment. For other cell 
types, random fields were imaged until n > 500 cells. Each dividing cell was considered 
one cell.  
Doubling time calculations. Cells were seeded (1-1.5x105 per 60-mm dish), and total 
cell counts were taken by hemocytometer every 24 hours for 4 days. Alternatively, cells 
were seeded (2.5-5.0x103 per well, 96-well plates), and the absorbance from an MTS-
based colorimetric assay (#G3582; Promega Corp.) was used to estimate cell counts 
every 24 hours. Timepoints vs. Log10(average cell counts or absorbance at that time) was 
plotted and the slope ascertained. T1/2 = Log10(2)/ slope. For some cell lines, both 
methods were used and gave similar results. 
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MBd localization assays. Extracellular trypsin treatment: MKLP1-GFP-expressing 
HeLa cells grown in MatTek dishes were imaged every 3 min, and underwent no 
morphological changes upon replacement of media with PBS. After trypsin addition, 
GFP+ MBds were monitored for 60-90 min for intensity reduction (degradation) or 
detachment from cells (dissociation).   
Co-culture assay: Equal numbers of monomeric RFP- or MKLP-GFP-expressing cells 
were seeded and co-cultured in 60-mm dishes with coverslips. Cells were stained 2 days 
later, and the percentage of GFP+ MBds associated with RFP+ cells was determined.    
FPP assay: The FPP assay was carried out as reported (Lorenzet al., 2006) except cells 
were plated in MatTek dishes 24 hours before co-transfection of MKLP1-GFP and 
GAPDH-dsRed (Lipofectamine 2000, Invitrogen). Cells were permeabilized and then 
digested with proteinase K (50 µg ml-1). Constructs labeling mitochondria, peroxisomes, 
endoplasmic reticulum and Golgi were used as controls. 
Lysosome and proteasome assays. Cells at 70% confluency were incubated with 
chloroquine (200 µM/PBS; Sigma), E64d + pepstatin A (E64d/PepA) (10 µg ml-1/DMSO 
each; Sigma; Komatsu et al., 2007; Klionsky et al., 2008) or solvents alone (controls) for 
22 hours before fixation. Lysosome inhibition was confirmed and visualized after 12-
hour DQ-Red BSA (10 µl ml-1; Invitrogen) incubation. Mitotic hRPE-1 cells were treated 
with proteasome inhibitors, MG132 (1 µM; Sigma) or lactacystin (50 µM; Sigma) 1 hour 
after replating.  
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Autophagy manipulation assays. MBds were quantified in more than 500 cells in 
triplicate unless otherwise noted. 
Protein depletion: siRNAs targeting human Atg7 (Yu et al., 2004), p62 (Pohl and Jentsh, 
2009), NBR1 (Kirkin et al., 2009; 2503-2521 base pairs, GenBank NM 005899), Lamin 
A/C (Gromley et al., 2005), and GFP (5’-NNCAUGAAGCAGCACGACUUC-3’) were 
from Dharmacon. MBd levels were analyzed 48 hours after 1 nmol siRNA transfection 
(Oligofectamine, Invitrogen) in HeLa cells, whereas in U2OS cells MBd levels were 
analyzed 30 hours after 100 nM siRNA transfection (Nucleofector, Amaxa) as previously 
described (Pohl and Jentsch, 2009). For NBR1 and p62 experiments, only cells negative 
for p62 and/or NBR1 immunofluorescence were analyzed.  
Beclin1 (BECN1) overexpression: MBd levels were analyzed in 265 Flag+ and 2200 
control MCF-7 cells 48 hours after Flag-BECN1 (4 µg) or mock nucleofection (Amaxa).  
LiCl + rapamycin treatment: MBd levels in HeLa cells were examined 24 hours after 
treatment with LiCl (10 mM; Sigma) and rapamycin (200 nM; Calbiochem), or with 
DMSO.  
CEP55-EGFP overexpression: MBd levels and its NBR1-association were assessed in 
hRPE-1 cells (1X105 per well, six-well plates) 48 hours after CEP55-EGFP (1 µg), EGFP 
(1 µg), or mock transfection.   
Bafilomycin A1 treatment: HeLa cells were transfected with siRNA against Lamin or NBR1 as 
described above for 24 hours before bafilomycin A1 (100 nM; Sigma) was added to block the 
fusion of autophagosomes with lysosomes. Twenty-two hours after bafilomycin A1 treatment, 
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cells were fixed and immunostained.  
Biochemical assays. Protease and phosphatase inhibitors, cell lysates, SDS-PAGE and 
immunoblotting were purchased or carried out as described (Gromley et al., 2005) unless 
specified. 
Autophagy activity: The activity of autophagy was determined by measuring autophagy 
flux: the amount of autophagic cargo that is delivered to lysosomes for degradation (i.e. 
the amount of autophagic cargo that is accumulated upon lysosomal inhibition in a given 
time period). E64d/PepA treatment was used to block lysosomal enzyme activity and 
lipidated LC3 (LC3-II), an autophagic cargo, was used to assess autophagic flux (Bjorkoy 
et al., 2005; Komatsu et al., 2007; Mizushima and Yoshimori, 2007; Klionsky et al., 
2008). Lysates of E64d/PepA and DMSO treated cells were blotted for a-tubulin and 
LC3. LC3-II levels were then determined and normalized to a-tubulin using ImageJ. 
Autophagic flux = 100 [1– (LC3-II level in control lysates/ LC3-II level in E64d/PepA 
treated lysates)]. 
Immunoprecipitation: hRPE-1 cell lysates (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 2 
mM EDTA, 1 mM EGTA, 1% Triton X-100, 10% glycerol, 4°C) were pre-cleared for 1 
hour with protein G-plus conjugated agarose beads (Santa Cruz) at 4°C, incubated with 2 
µg normal IgG, anti-Cep55 or anti-NBR1 antibodies for 3 hours at 4°C, and incubated 
overnight at 4°C with 25 µl protein G-plus beads. Following washes with lysis buffer and 
elution, immunoprecipitated proteins were analyzed by SDS-PAGE and immunoblotting.  
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Assays for MBd function. Cellular reprogramming: Viral production, transduction and 
reprogramming were performed as described (Yu et al., 2007; Park et al., 2008, Chan et 
al., 2009, Loewer et al., 2010). Commercially-available shRNA against NBR1 (pSM2c-
shNBR1, V2MM_36901; 4-22bp, GenBank NM 005899) was cloned into pGIPZ 
lentiviral vector (Open Biosystems). Embryonic fibroblasts (IMR90), adult fibroblasts 
(hFib2) and dH1f cells were transduced with either NBR1-specfic or non-targeting 
shRNA vector, and puromycin-selected to establish NBR1-depleted (shNBR1) and 
control (shNT) lines. dH1f (2.5X104 per assay) were reprogrammed with lentiviral 
vectors (Yu et al., 2009; Addgene #21162 and 21164) expressing OCT4, SOX2, KLF4 
and c-MYC (Park et al., 2008, Chan et al., 2009, Loewer et al., 2010) whereas the 
reprogramming of IMR90 and hFib2 cells (5X104 per assay) also included lentiviral 
vectors expressing Nanog and Lin28 (Yu et al., 2007, 2009; Addgene #21163). iPSC 
colonies were quantified on day 21 based on Tra-1-60 expression using ImageJ, as 
reported (Chan et al., 2009; Loewer et al., 2010) and with parameters: ≥148 (threshold), 
0.5-1 (circularity), and either 10-infinity or 30-infinity (size).   
Side Population (SP) assay: The assays were carried out as previously described 
(Engelmann et al., 2008) in MCF-7 cells. The MBd levels in SP and non-SP populations 
were determined as described above.  
Soft-agar assays: “MBd high” and “MBd low” subpopulations of MKLP1-GFP-
expressing HeLa cells were separated by FACS, and plated in soft-agar (2.5 x104 per 
well, 6-well plates). The MBd levels were determined 12-15 hours after plating aliquots 
95
of subpopulations onto coverslips. For the NBR1-silencing soft-agar assay, NBR1-
depleted (shNBR1) and control (shNT) cells (1x105 per 100-mm dish) were plated. For 
both assays, cells were grown for ~3 weeks at 37°C, and stained as described (Sachdev et 
al., 2009). Colonies were quantified microscopically, and the average from triplicate 
wells or plates presented. 
Antibodies. Antibodies to the following proteins/tags were used in this study: Atg5 
(1:2000, Cosmo Bio, CAC-TMD-PH-ATG); Atg7 (1:1000, ProSci, 3617); Actin (1:300, 
Sigma, AC-40); Aurora B (1:100, BD Trans Lab, 611082); CD13 (1:50, BioLegend, 
301707); CD133 (1:200, eBioscience, 14-1331); Cep55 (1:50, 1:100 and 1:1000 for 
immunofluorescence, Abnova #H00055165-B01, Abnova #H00055165-A01, and the gift 
from K. Kurtche, respectively; 1:500 for immunoblotting, Genetax #GTX112190); 
hCenexin1 (1:100, a gift from K.S. Lee); Centriolin (1:200, ref. 9); Flag (1:200, Sigma, 
F7425); GAPDH (1:8000; Santa Cruz, SC-32233); GFP (1:1000; Abcam, ab6556 and 
Santa Cruz, sc-9996); GT335 (1:100; a gift from P. Denoulet); b1-Integrin (1:50; BD 
Phramingen); K15 (1:100; Lab Vision, MS-1068-P); LC3 (1:10 for immunofluorescence, 
Nano Tools, LC3-5F10; 1:300 for immunoblotting, Novus Bio NB100-2331); LAMP2 
(1:50, H4B4 from DSHB); mgcRACGAP (1:500, Abcam, ab2270); MKLP1 (1:1000 for 
immunofluorescence, 1:200 for immunohistochemistry, 1:10 for immuno-EM, Santa 
Cruz, sc-867); NBR1 (1:500, Abnova, H00004077-B01P); p62, human samples (1:500, 
BD Trans Lab, 610833); p62, mouse samples (1:1000, Progen, GP62-C); RFP (1:200, 
Clontech, 632496); Na-K-ATPase (1:15, a6F from DSHB); α -tubulin (1:100 for 
immunofluorescence, 1:400 for immunoblotting, Sigma, T9026a; 1:100 for 
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immunofluorescence, Millipore, CBL270); α -tubulin-FITC (1:300, Sigma, F2168); Tra-
1-60-biotin (1:200, eBioscience, 13-8863); Ubiquitin (1:2000, BD BioSci, #550944); 
WGA-Alexa Fluor 555 (1:200, Molecular Probes, W32464); ZO-1-FITC (1:50, Zymed, 
33-9111).  
Statistics. Data was analyzed by Student’s one-tailed paired t-test or unpaired with 
Welch’s correction unless specified. One-way ANOVA was used in conjunction with 
Tukey’s test for comparisons among multiple groups. For the EdU-labeling assay, the 
EdU intensity was first logarithmically transformed for the use of one-way ANOVA. 
Statistically analyzed experiments were completed at least 3 times. 
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Chapter III: 
Cell lines and plasmids. MAP vector was kindly provided by Dr. Dannel McCollum 
(University of Massachusetts Medical School; Ma et al., 2012). Plasmid pEGFP-p62 was 
a gift from Dr. Terje Johansen (University of Tromsø, Tromsø, Norway; Lamark et al., 
2003). Alfy truncations (pDEST-Tomato-Alfy) were described previously (Filimonenko 
et al., 2010) and were kindly provided by Dr. Anne Simonsen (University of Oslo, Oslo, 
Norway). Establishment and cell synchronization of U2OS cells expressing NBR1-MAP 
or MAP were performed based on Ma et al., 2012. 
NBR1, p62, or Alfy overexpression. MBd levels were assessed in HeLa cells (1X105 per 
well, 6-well plates) 48 hours after plasmid cDNA transfection (1 µg for all plasmids) 
Transfection was carried out using Fugene 6 (Roche).   
Comparative Proteomics. The protein set for the p62 interactions was obtained from 
Behrends et al., 2010. For proteins identified in this study, the unique UniProt accessions 
were mapped to gene names using UniProt KB. Accessions that didn't map successfully 
in UniProt KB were manually analyzed. These lists of proteins were then compared in 
Microsoft Excel 2011 using PivotTable. 
Antibodies. Antibodies to the following proteins were used in this chapter: MKLP1 
(1:1000 for immunofluorescence, Santa Cruz, sc-867); MYH9 (1:50 for immuno-
fluorescence, Santa Cruz, sc-47199); NBR1 (1:50, Abnova, H00004077-B01P); PLK1 
(1:500, 05-844, EMD Millipore); α-tubulin (1:100 for immunofluorescence, Millipore, 
CBL270). 
98
REFERENCES 
Anderson, C.T. and Stearns, T. (2009). Centriole age underlies asynchronous primary 
cilium growth in mammalian cells. Curr. Biol. 19, 1498-502. 
Barr, F.A. and Gruneberg, U. (2007). Cytokinesis: placing and making the final cut. Cell, 
131, 847-60. 
Barroca, V. et al. (2009). Mouse differentiating spermatogonia can generate germinal 
stem cells in vivo. Nat. Cell Biol. 11, 190-6.  
Behrends, C., Sowa, M. E., Gygi, S. P., & Harper, J. W. (2010). Network organization of 
the human autophagy system. Nature, 466(7302), 68–76.  
Berry, D. L., & Baehrecke, E. H. (2007). Growth Arrest and Autophagy Are Required for 
Salivary Gland Cell Degradation in Drosophila. Cell, 131(6), 1137–1148.  
Bilgüvar, K. et al., (2010). Whole-exome sequencing identifies recessive WDR62 
mutations in severe brain malformations. Nature 467, 207-10. 
Bjorkoy, G. et al. (2005). p62/SQSTM1 forms protein aggregates degraded by autophagy 
and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603-14. 
Carlton, J.G., and Martin-Serrano, J. (2007). Parallels between cytokinesis and retroviral 
budding: a role for the ESCRT machinery. Science 316, 1908–1912.  
Cecconi, F. and Levine, B. (2008). The role of autophagy in mammalian development: 
cell makeover rather than cell death. Dev. Cell 15, 344-57.  
Cemma, M., Kim, P. K., & Brumell, J. H. (2011). The ubiquitin-binding adaptor proteins 
p62/SQSTM1 and NDP52 are recruited independently to bacteria-associated 
microdomains to target Salmonella to the autophagy pathway. Autophagy, 7(3), 341–345. 
Chai, Y., Tian, D., Yang, Y., Feng, G., Cheng, Z., Li, W., & Ou, G. (2012). Apoptotic 
regulators promote cytokinetic midbody degradation in C. elegans. J Cell Biol. 199 
(7):1047-55. 
Chan, E.M. et al. (2009). Live cell imaging distinguishes bona fide human iPS cells from 
partially reprogrammed cells. Nat. Biotechnol. 27, 1033-7.  
Chen, C.-H., Lu, P.-J., Chen, Y.-C., Fu, S.-L., Wu, K.-J., Tsou, A.-P., et al. (2007). 
FLJ10540-elicited cell transformation is through the activation of PI3-kinase/AKT 
pathway. Oncogene, 26(29), 4272–4283.  
99
Clausen, T. H., Lamark, T., Isakson, P., Finley, K., Larsen, K. B., Brech, A., et al. (2010). 
p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their 
degradation by autophagy. Autophagy, 6(3), 330–344.  
Conboy, M.J., Cerletti, M., Wagers, A.J. and Conboy, I.M. (2010). Immuno-analysis and 
FACS sorting of adult muscle fiber-associated stem/precursor cells. Methods Mol. Biol. 
621, 165-73. 
Copp, J., Manning, G., & Hunter, T. (2009). TORC-specific phosphorylation of 
mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR 
signaling complex 2. Cancer research, 69(5), 1821–1827.  
Doxsey, S., McCollum, D. and Theurkauf, W. (2005). Centrosomes in cellular regulation. 
Annu. Rev. Cell Dev. Biol. 21, 411-34.  
Dubreuil, V. et al. (2007). Midbody and primary cilium of neural progenitors release 
extracellular membrane particles enriched in the stem cell marker prominin-1. J. Cell 
Biol. 176, 483-95. 
Eggert, U.S., Mitchison, T.J. and Field, C.M. (2006). Animal cytokinesis: from parts list 
to mechanisms. Annu. Rev. Biochem. 75, 543-66.  
Elizabeth Deosaran, Kenneth B Larsen, Rong Hua, Graeme Sargent, Yuqing Wang, 
Sarah Kim, Trond Lamark, Miluska Jauregui, Kelsey Law, Jennifer Lippincott-Schwartz, 
Andreas Brech, Terje Johansen, and Peter K Kim. (2012) NBR1 acts as an autophagy 
receptor for peroxisomes. JCS online publication date 13 December 2012.  
Engelmann, K., Shen, H., and Finn, O.J. (2008). MCF7 side population cells with 
characteristics of cancer stem/progenitor cells express the tumor antigen MUC1. Cancer 
Res. 68, 2419-26.   
Eskelinen, E.L., Tanaka, Y. and Saftig, P. (2003). At the acidic edge: emerging functions 
for lysosomal membrane proteins. Trends Cell Biol. 13, 137-45.  
Fan, W., Tang, Z., Chen, D., Moughon, D., Ding, X., Chen, S., et al. (2010). Keap1 
facilitates p62-mediated ubiquitin aggregate clearance via autophagy. Autophagy, 6(5), 
614–621.  
Fededa, J. P. & Gerlich, D. W. (2012). Molecular control of animal cell cytokinesis. 
Nature Cell Biol. 14, 440–447.  
100
Fielding, A.B. et al. (2005) Rab11–FIP3 and FIP4 interact with Arf6 and the exocyst to 
control membrane traffic in cytokinesis. EMBO J. 24, 3389–3399.  
Filimonenko, M., Isakson, P., Finley, K. D., Anderson, M., Jeong, H., Melia, T. J., et al. 
(2010). The selective macroautophagic degradation of aggregated proteins requires the 
PI3P-binding protein Alfy. Molecular Cell, 38(2), 265–279.  
Fimia, G.M. et al. (2007). Ambra1 regulates autophagy and development of the nervous 
system. Nature 447, 1121-5.  
Fuchs, E. (2009). The tortoise and the hair: slow-cycling cells in the stem cell race. Cell 
137, 811-9.  
Furuya, T., Kim, M., Lipinski, M., Li, J., Kim, D., Lu, T., et al. (2010). Negative 
regulation of Vps34 by Cdk mediated phosphorylation. Molecular Cell, 38(4), 500–511.  
Gamerdinger M, Hajieva P, Kaya AM, Wolfrum U, Hartl FU, Behl C. (2009). Protein 
quality control during aging involves recruitment of the macroautophagy pathway by 
BAG3. Embo J; 28: 889–901.  
Gal, J., Ström, A.-L., Kwinter, D. M., Kilty, R., Zhang, J., Shi, P., et al. (2009). 
Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-
independent mechanism. Journal of Neurochemistry, 111(4), 1062–1073.  
Gao, C., Cao, W., Bao, L., Zuo, W., Xie, G., Cai, T., et al. (2010). Autophagy negatively 
regulates Wnt signalling by promoting Dishevelled degradation. Nature Cell Biology, 
12(8), 781–790.  
Geir Bjørkøy, Trond Lamark, Andreas Brech, Heidi Outzen, Maria Perander, Aud 
Overvatn, Harald Stenmark, and Terje Johansen. (2005). p62/SQSTM1 forms protein 
aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell 
death., 171(4), 603–614.  
Green, R. A., Paluch, E. & Oegema, K. (2012). Cytokinesis in animal cells. Annu. Rev. 
Cell Dev. Biol. 28, 29–58.  
Greenbaum, M.P., Ma, L., and Matzuk, M.M. (2007). Conversion of midbodies into germ 
cell intercellular bridges. Dev. Biol. 305, 389-96.  
Gromley, A. et al. (2005). Centriolin anchoring of exocyst and SNARE complexes at the 
midbody is required for secretory-vesicle-mediated abscission. Cell 123, 75-87.   
101
Goss, J.W. and Toomre, D.K. (2008). Both daughter cells traffic and exocytose 
membrane at the cleavage furrow during mammalian cytokinesis. J. Cell Biol. 181, 1047-
54.  
Guo, Y., Chang, C., Huang, R., Liu, B., Bao, L., & Liu, W. (2012). AP1 is essential for 
generation of autophagosomes from the trans-Golgi network. Journal of cell science, 
125(Pt 7), 1706–1715.  
Hara, T. et al. (2006). Suppression of basal autophagy in neural cells causes 
neurodegenerative disease in mice. Nature 441, 885-9.  
Hara, T., Takamura, A., Kishi, C., Iemura, S.-I., Natsume, T., Guan, J.-L., & Mizushima, 
N. (2008). FIP200, a ULK-interacting protein, is required for autophagosome formation 
in mammalian cells. The Journal of cell biology, 181(3), 497–510.  
Holtrich, U., Wolf, G., Bräuninger, A., Karn, T., Böhme, B., Rübsamen-Waigmann, H., 
& Strebhardt, K. (1994). Induction and down-regulation of PLK, a human 
serine/threonine kinase expressed in proliferating cells and tumors. Proceedings of the 
National Academy of Sciences of the United States of America, 91(5), 1736–1740. 
Hu, C.-K., Ozlü, N., Coughlin, M., Steen, J. J., & Mitchison, T. J. (2012). Plk1 negatively 
regulates PRC1 to prevent premature midzone formation before cytokinesis. Molecular 
biology of the cell, 23(14), 2702–2711.  
Hu, C.-K., Coughlin, M., & Mitchison, T. J. (2012). Midbody Assembly and its 
Regulation during Cytokinesis. Molecular biology of the cell.  
Huang DW, Sherman BT, Lempicki RA. (2009). Systematic and integrative analysis of 
large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 4(1):44-57. 
Huang DW, Sherman BT, Lempicki RA. (2009). Bioinformatics enrichment tools: paths 
toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 
37(1):1-13.   
Hurley, J. H. and Hanson, P. I. (2010). Membrane budding and scission by the ESCRT 
machinery: it’s all in the neck. Nat. Rev. Mol. Cell Biol. 11, 556-566.  
Inoda, S., Hirohashi, Y., Torigoe, T., Nakatsugawa, M., Kiriyama, K., Na- kazawa, E., 
Harada, K., Takasu, H., Tamura, Y., Kamiguchi, K., Asanuma, H., Tsuruma, T., Terui, 
T., Ishitani, K., Ohmura, T., Wang, Q., Greene, M. I., Hasegawa, T., Hirata, K., and Sato, 
N. (2009). Cep55/c10orf3, a tumor antigen derived from a centrosome-residing protein in 
breast carcinoma. J. Immunother. 32, 474 – 485  
 
102
Isakson, P., Bjørås, M., Bøe, S. O., & Simonsen, A. (2010). Autophagy contributes to 
therapy-induced degradation of the PML/RARA oncoprotein. Blood, 116(13), 2324–
2331.  
Itakura E, Mizushima N. (2010). Characterization of autophagosome formation site by a 
hierarchical analysis of mammalian Atg proteins. Autophagy 6:764–76  
Johnston, J.A., Illing, M.E. and Kopito, R.R. (2002). Cytoplasmic dynein/dynactin 
mediates the assembly of aggresomes. Cell Motil. Cytoskeleton 53, 26-38.  
Joseph, N., Hutterer, A., Poser, I., & Mishima, M. (2012). ARF6 GTPase protects the 
post-mitotic midbody from 14-3-3-mediated disintegration. The EMBO Journal, 31(11), 
2604–2614.  
Kaushik et al., (2008). Constitutive Activation of Chaperone-mediated Autophagy in 
Cells with Impaired Macroautophagy. Mol. Biol. Cell 19, 2179-92.  
Kim, P. K., Hailey, D. W., Mullen, R. T., & Lippincott-Schwartz, J. (2008). Ubiquitin 
signals autophagic degradation of cytosolic proteins and peroxisomes. Proceedings of the 
National Academy of Sciences of the United States of America, 105(52), 20567–20574.  
Kirkin, V., Lamark, T., Sou, Y.-S., Bjørkøy, G., Nunn, J. L., Bruun, J.-A., et al. (2009a). 
A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. Molecular 
cell, 33(4), 505–516.  
Kirkin, V., McEwan, D. G., Novak, I., & Dikic, I. (2009b). A role for ubiquitin in 
selective autophagy. Molecular cell, 34(3), 259–269.  
Klionsky, D.J. et al. (2008). Guidelines for the use and interpretation of assays for 
monitoring autophagy in higher eukaryotes. Autophagy 4, 151-75.  
Komatsu, M. et al. (2005). Impairment of starvation-induced and constitutive autophagy 
in Atg7-deficient mice. J. Cell Biol. 169, 425-34. 
Komatsu, M. et al. (2007). Homeostatic levels of p62 control cytoplasmic inclusion body 
formation in autophagy-deficient mice. Cell 131, 1149-63.  
Kraft, C., Deplazes, A., Sohrmann, M., and Peter, M. (2008). Mature ribosomes are 
selectively degraded upon starvation by an autophagy pathway requiring the 
Ubp3p/Bre5p ubiquitin protease. Nat. Cell Biol. 10, 602– 610.  
103
Kristensen, A. R., Schandorff, S., Høyer-Hansen, M., Nielsen, M. O., Jäättelä, M., 
Dengjel, J., & Andersen, J. S. (2008). Ordered organelle degradation during starvation-
induced autophagy. Molecular & Cellular Proteomics : MCP, 7(12), 2419–2428.  
Kuma, A., Hatano, M., Matsui, M., Yamamoto, A., Nakaya, H., Yoshimori, T., et al. 
(2004). The role of autophagy during the early neonatal starvation period. Nature, 
432(7020), 1032–1036.  
Lamark, T., Perander, M., Outzen, H., Kristiansen, K., Øvervatn, A., Michael- sen, E., 
Bjørkøy, G., and Johansen, T. (2003). Interaction codes within the family of mammalian 
Phox and Bem1p domain-containing proteins. J. Biol. Chem. 278, 34568-81.   
Laplante, M., & Sabatini, D. M. (2012). mTOR signaling in growth control and disease. 
Cell, 149(2), 274–293.  
Lee, C., Fotovati, A., Triscott, J., Chen, J., Venugopal, C., Singhal, A., et al. (2012). 
Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part 
through loss of SOX2 and delays tumor progression in mice. Stem Cells (Dayton, Ohio), 
30(6), 1064–1075.  
Lee, H. H., Elia, N., Ghirlando, R., Lippincott-Schwartz, J., & Hurley, J. H. (2008). 
Midbody targeting of the ESCRT machinery by a noncanonical coiled coil in CEP55. 
Science (New York, NY), 322(5901), 576–580.  
Lekomtsev, S., Su, K.-C., Pye, V. E., Blight, K., Sundaramoorthy, S., Takaki, T., et al. 
(2012). Centralspindlin links the mitotic spindle to the plasma membrane during 
cytokinesis. Nature, 492(7428), 276–279.  
Levine, B. and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. Cell 132, 
27-42.  
Liang, X.H. et al. (1999). Induction of autophagy and inhibition of tumorigenesis by 
beclin 1. Nature 402, 672-6.  
Linares, J. F., Amanchy, R., Diaz-Meco, M. T., & Moscat, J. (2011). Phosphorylation of 
p62 by cdk1 controls the timely transit of cells through mitosis and tumor cell 
proliferation. Molecular and cellular biology, 31(1), 105–117.  
Lipinski, M. M., Hoffman, G., Ng, A., Zhou, W., Py, B. F., Hsu, E., et al. (2010). A 
genome-wide siRNA screen reveals multiple mTORC1 independent signaling pathways 
regulating autophagy under normal nutritional conditions. Developmental Cell, 18(6), 
1041–1052.  
104
Loewer, S. et al., (2010). Large intergenic non-coding RNA-RoR modulates 
reprogramming of human induced pluripotent stem cells. Nat. Genet. 42, 1113-7.  
Lorenz, H., Hailey, D.W. and Lippincott-Schwartz, J. (2006). Fluorescence protease 
protection of GFP chimeras to reveal protein topology and subcellular localization. Nat. 
Methods 3, 205-10.  
Ma, H., McLean, J. R., Chao, L. F.-I., Mana-Capelli, S., Paramasivam, M., Hagstrom, K. 
A., et al. (2012). A highly efficient multifunctional tandem affinity purification approach 
applicable to diverse organisms. Molecular & Cellular Proteomics : MCP, 11(8), 501–
511.  
Ma, N., Tulu, U. S., Ferenz, N. P., Fagerstrom, C., Wilde, A., & Wadsworth, P. (2010). 
Poleward transport of TPX2 in the mammalian mitotic spindle requires dynein, Eg5, and 
microtubule flux. Molecular biology of the cell, 21(6), 979–988. doi:10.1091/mbc.E09-
07-0601 
Majeski, A.E. and Dice, J.F. (2004). Mechanisms of chaperone-mediated autophagy. Int. 
J. Biochem. Cell Biol. 36, 2435-44.  
Mao, J.-Z., Jiang, P., Cui, S.-P., Ren, Y.-L., Zhao, J., Yin, X.-H., et al. (2012). Girdin 
locates in centrosome and midbody and plays an important role in cell division. Cancer 
science, 103(10), 1780–1787.  
Marchbank, K., Waters, S., Roberts, R. G., Solomon, E., & Whitehouse, C. A. (2012). 
MAP1B Interaction with the FW Domain of the Autophagic Receptor Nbr1 Facilitates Its 
Association to the Microtubule Network. International Journal of Cell Biology, 2012, 
208014.  
Mardakheh, F. K., Auciello, G., Dafforn, T. R., Rappoport, J. Z., & Heath, J. K. (2010). 
Nbr1 is a novel inhibitor of ligand-mediated receptor tyrosine kinase degradation. 
Molecular and Cellular Biology, 30(24), 5672–5685.  
Marson, A., Foreman, R., Chevalier, B., Bilodeau, S., Kahn, M., Young, R. A., & 
Jaenisch, R. (2008). Wnt signaling promotes reprogramming of somatic cells to 
pluripotency. Cell stem cell, 3(2), 132–135.  
Marzesco, A.M. et al. (2005). Release of extracellular membrane particles carrying the 
stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. 
J. Cell Sci. 118, 2849-58. 
105
Matsumoto, G., Wada, K., Okuno, M., Kurosawa, M., & Nukina, N. (2011). Serine 403 
Phosphorylation of p62/SQSTM1 Regulates Selective Autophagic Clearance of 
Ubiquitinated Proteins. Molecular Cell, 44(2), 279–289.  
Matsunaga K, Morita E, Saitoh T, Akira S, Ktistakis NT, et al. (2010). Autophagy 
requires endoplasmic reticulum targeting of the PI3-kinase complex via Atg14L. J. Cell 
Biol. 190:511–21 
Menon, S., & Manning, B. D. (2008). Common corruption of the mTOR signaling 
network in human tumors. Oncogene, 27 Suppl 2, S43–51.  
Mishima, M., Kaitna, S. & Glotzer, M. (2002). Central spindle assembly and cytokinesis 
require a kinesin-like protein/RhoGAP complex with microtubule bundling activity. Dev. 
Cell 2, 41–54.  
Mitchison, T., Evans, L., Schulze, E. and Kirschner, M. (1986). Sites of microtubule 
assembly and disassembly in the mitotic spindle. Cell 45, 515-27.  
Mizushima, N., and Klionsky, D. (2007). Protein turnover via autophagy: implications 
for metabolism. Annu. Rev. Nutr. 27, 19–40.  
Mizushima, N., & Levine, B. (2010). Autophagy in mammalian development and 
differentiation. Nature cell biology, 12(9), 823–830.  
Mizushima, N., Levine, B., Cuervo, A.M. and Klionsky, D.J. (2008). Autophagy fights 
disease through cellular self-digestion. Nature 451, 1069-75.  
Mizushima, N. and Yoshimori, T. (2007). How to interpret LC3 immunoblotting. 
Autophagy 3, 542-5.  
Mizushima, N., & Yoshimori, T. (2011). The Role of Atg Proteins in Autophagosome 
Formation - Annual Review of Cell and Developmental Biology, 27(1):107. Annual 
Review of Cell 
Mondal, G., Rowley, M., Guidugli, L., Wu, J., Pankratz, V. S., & Couch, F. J. (2012). 
BRCA2 localization to the midbody by filamin A regulates cep55 signaling and 
completion of cytokinesis. Developmental cell, 23(1), 137–152.  
Morita, E. et al. (2007). Human ESCRT and ALIX proteins interact with proteins of the 
midbody and function in cytokinesis. EMBO J. 26, 4215–4227.  
Morris, R.J. et al. (2004). Capturing and profiling adult hair follicle stem cells. Nat. 
Biotechnol. 22, 411-7.  
106
Mukai, A., Mizuno, E., Kobayashi, K., Matsumoto, M., Nakayama, K. I., Kitamura, N., 
& Komada, M. (2008). Dynamic regulation of ubiquitylation and deubiquitylation at the 
central spindle during cytokinesis. Journal of Cell Science, 121(Pt 8), 1325–1333.  
Mullins, J.M. and Biesele, J.J. (1977). Terminal phase of cytokinesis in D-98s cells. J. 
Cell Biol. 73, 672-84.  
Nedelsky, N. et al. (2008). Autophagy and the ubiquitin-proteasome system: 
collaborators in neuroprotection. Biochim. Biophys. Acta. 1782, 691-9.  
Neumüller, R.A. and Knoblich, J.A. (2009). Dividing cellular asymmetry: asymmetric 
cell division and its implications for stem cells and cancer. Genes Dev. 23, 2675-99.  
Oatley, J.M. and Brinster, R.L. (2008). Regulation of spermatogonial stem cell self-
renewal in mammals. Annu. Rev. Cell Dev. Biol. 24, 263-86.  
O'Brien, C.A., Pollett, A., Gallinger, S. and Dick, J.E. (2007). A human colon cancer cell 
capable of initiating tumour growth in immunodeficient mice. Nature 445, 106-10.  
O'Brien, R. N., Shen, Z., Tachikawa, K., Lee, P. A., & Briggs, S. P. (2010). Quantitative 
proteome analysis of pluripotent cells by iTRAQ mass tagging reveals post-
transcriptional regulation of proteins required for ES cell self-renewal. Molecular & 
Cellular Proteomics : MCP, 9(10), 2238–2251. 
Ogawa M, Yoshikawa Y, Kobayashi T, Mimuro H, Fukumatsu M, Kiga K et al. (2011). 
A Tecpr1- dependent selective autophagy pathway targets bacterial pathogens. Cell Host 
Microbe. 9: 376–389. 
Orenstein, S. J., & Cuervo, A. M. (2010). Chaperone-mediated autophagy: molecular 
mechanisms and physiological relevance. Seminars in Cell & Developmental Biology, 
21(7), 719–726.  
Orvedahl, A., MacPherson, S., Sumpter, R., Tallóczy, Z., Zou, Z., & Levine, B. (2010). 
Autophagy protects against Sindbis virus infection of the central nervous system. Cell 
Host & Microbe, 7(2), 115–127.  
Pankiv, S. et al. (2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate 
degradation of of ubiquitinated protein aggregates by autophagy. J. Biol. Chem. 282, 
24131-45.  
Pardal, R., Clarke, M.F. and Morrison, S.J. (2003). Applying the principles of stem-cell 
biology to cancer. Nat. Rev. Cancer 3, 895-902.  
107
Park, I.H. et al. (2008). Reprogramming of human somatic cells to pluripotency with 
defined factors. Nature 451, 141-6.  
Pavicic-Kaltenbrunner, V., Mishima, M. & Glotzer, M. (2007). Cooperative assembly of 
CYK-4/MgcRacGAP and ZEN-4/MKLP1 to form the centralspindlin complex. Mol. 
Biol. Cell 18, 4992–5003.  
Pece, S. et al. (2010). Biological and molecular heterogeneity of breast cancers correlates 
with their cancer stem cell content. Cell 140, 62-73.  
Peterson, R. T., Beal, P. A., Comb, M. J., & Schreiber, S. L. (2000). FKBP12-rapamycin-
associated protein (FRAP) autophosphorylates at serine 2481 under translationally 
repressive conditions. The Journal of biological chemistry, 275(10), 7416–7423. 
Piel, M., Meyer, P., Khodjakov, A., Rieder, C.L. and Bornens, M. (2000). The respective 
contributions of the mother and daughter centrioles to centrosome activity and behavior 
in vertebrate cells. J. Cell Biol. 149, 317-30. 
Pohl, C., & Jentsch, S. (2008). Final stages of cytokinesis and midbody ring formation 
are controlled by BRUCE. Cell, 132(5), 832–845.  
Pohl, C. and Jentsch, S. (2009). Midbody ring disposal by autophagy is a post-abscission 
event of cytokinesis. Nat. Cell Biol. 11, 65-70.  
Rawi, Al, S., Louvet-Vallée, S., Djeddi, A., Sachse, M., Culetto, E., Hajjar, C., et al. 
(2011). Postfertilization autophagy of sperm organelles prevents paternal mitochondrial 
DNA transmission. Science (New York, NY), 334(6059), 1144–1147.  
Rujano, M.A. et al. (2006). Polarised asymmetric inheritance of accumulated protein 
damage in higher eukaryotes. PLoS Biol. 4, 2325-2335.  
Sachdev, S., Bu, Y., and Gelman, I.H. (2009). Paxillin-Y118 phosphorylation contributes 
to the control of Src-induced anchorage-independent growth by FAK and adhesion. BMC 
Cancer 12, 9:12.  
Sahu, R., Kaushik, S., Clement, C. C., Cannizzo, E. S., Scharf, B., Follenzi, A., et al. 
(2011). Microautophagy of cytosolic proteins by late endosomes. Developmental Cell, 
20(1), 131–139.  
Salic, A. and Mitchison, T.J. (2008). A chemical method for fast and sensitive detection 
of DNA synthesis in vivo. Proc. Natl. Acad. Sci. U.S.A. 105, 2415-20.  
108
Sarkar, S. et al. (2005). Lithium induces autophagy by inhibiting inositol 
monophosphatase. J. Cell Biol. 170, 1101-11.  
Sarkar, S. et al. (2008). A rational mechanism for combination treatment of Huntington's 
disease using lithium and rapamycin. Hum. Mol. Genet. 17, 170-8.  
Sato, K. et al. (2007). Autophagy is activated in colorectal cancer cells and contributes to 
the tolerance to nutrient deprivation. Cancer Res. 67, 9677-84. 
 Sato, M., & Sato, K. (2011). Degradation of paternal mitochondria by fertilization-
triggered autophagy in C. elegans embryos. Science (New York, NY), 334(6059), 1141–
1144.  
Sandilands E, Serrels B, McEwan DG, Morton JP, Macagno JP, McLeod K et al. (2011). 
Autophagic targeting of Src promotes cancer cell survival following reduced FAK 
signalling. Nat Cell Biol. 14: 51–60. 
Simonsen A, Birkeland HC, Gillooly DJ, Mizushima N, Kuma A, Yoshimori T, et al. 
(2004). Alfy, a novel FYVE- domain-containing protein associated with protein granules 
and autophagic membranes. J Cell Sci. 117:4239-51.  
Skop, A. R., Liu, H., Yates, J., Meyer, B. J., & Heald, R. (2004). Dissection of the 
mammalian midbody proteome reveals conserved cytokinesis mechanisms. Science (New 
York, NY), 305(5680), 61–66.  
Soliman, G. A., Acosta-Jaquez, H. A., Dunlop, E. A., Ekim, B., Maj, N. E., Tee, A. R., & 
Fingar, D. C. (2010). mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific 
Catalytic Activity and Clarifies Rapamycin Mechanism of Action. The Journal of 
biological chemistry, 285(11), 7866–7879.  
Steigemann, P. et al. (2009). Aurora B-mediated abscission checkpoint protects against 
tetraploidization. Cell 136, 473-84.   
Strome, S. (2005). Specification of the germ line. WormBook 28, 1-10. 
 Strebhardt, K., & Ullrich, A. (2006). Targeting polo-like kinase 1 for cancer therapy. 
Nature Reviews Cancer, 6(4), 321–330.  
Takai, N., Hamanaka, R., Yoshimatsu, J., & Miyakawa, I. (2005). Polo-like kinases 
(Plks) and cancer. Oncogene, 24(2), 287–291.  
109
Takaki, T., Trenz, K., Costanzo, V., & Petronczki, M. (2008). Polo-like kinase 1 reaches 
beyond mitosis--cytokinesis, DNA damage response, and development. Current Opinion 
in Cell Biology, 20(6), 650–660.  
Takenobu, H., Shimozato, O., Nakamura, T., Ochiai, H., Yamaguchi, Y., Ohira, M., et al. 
(2011). CD133 suppresses neuroblastoma cell differentiation via signal pathway 
modification. Oncogene, 30(1), 97–105.  
Tan, J. M. M., Wong, E. S. P., Kirkpatrick, D. S., Pletnikova, O., Ko, H. S., Tay, S.-P., et 
al. (2008). Lysine 63-linked ubiquitination promotes the formation and autophagic 
clearance of protein inclusions associated with neurodegenerative diseases. Human 
Molecular Genetics, 17(3), 431–439.  
Thurston TL, Ryzhakov G, Bloor S, von Muhlinen N, Randow F. (2009). The TBK1 
adaptor and autophagy receptor NDP52 restricts the proliferation of ubiquitin-coated 
bacteria. Nat Immunol. 10: 1215–1221.  
Tsukamoto, S., Kuma, A., Murakami, M., Kishi, C., Yamamoto, A., & Mizushima, N. 
(2008). Autophagy is essential for preimplantation development of mouse embryos. 
Science (New York, NY), 321(5885), 117–120.  
Tsvetkov, L., Xu, X., Li, J., & Stern, D. F. (2003). Polo-like kinase 1 and Chk2 interact 
and co-localize to centrosomes and the midbody. The Journal of biological chemistry, 
278(10), 8468–8475.  
Van der Horst, A., Simmons, J., & Khanna, K. K. (2009). Cep55 stabilization is required 
for normal execution of cytokinesis. Cell Cycle (Georgetown, Tex), 8(22), 3742–3749. 
Vazquez-Martin, A., Oliveras-Ferraros, C., Bernadó, L., López-Bonet, E., & Menendez, 
J. A. (2009). The serine 2481-autophosphorylated form of mammalian Target Of 
Rapamycin (mTOR) is localized to midzone and midbody in dividing cancer cells. 
Biochemical and biophysical research communications, 380(3), 638–643.  
Vazquez-Martin, A., Sauri-Nadal, T., Menendez, O. J., Oliveras-Ferraros, C., Cufí, S., 
Corominas-Faja, B., et al. (2012). Ser2481-autophosphorylated mTOR colocalizes with 
chromosomal passenger proteins during mammalian cell cytokinesis. Cell cycle 
(Georgetown, Tex), 11(22), 4211–4221.  
Vazquez P, Arroba AI, Cecconi F, de la Rosa EJ, Boya P, de Pablo F. (2012). Atg5 and 
Ambra1 differentially modulate neurogenesis in neural stem cells. Autophagy 8: 187- 
199. 
110
Visvader, J.E. and Lindeman, G.J. (2008). Cancer stem cells in solid tumours: 
accumulating evidence and unresolved questions. Nat. Rev. Cancer 8, 755-68.  
Wang, X. et al. (2009). Asymmetric centrosome inheritance maintains neural progenitors 
in the neocortex. Nature 461, 947-55.  
Wang, Z., Cao, L., Kang, R., Yang, M., Liu, L., Zhao, Y., et al. (2011). Autophagy 
regulates myeloid cell differentiation by p62/SQSTM1-mediated degradation of PML-
RARα oncoprotein. Autophagy, 7(4), 401–411. 
Watanabe, Y., & Tanaka, M. (2011). p62/SQSTM1 in autophagic clearance of a non-
ubiquitylated substrate. Journal of Cell Science, 124(Pt 16), 2692–2701.  
Waters, S. et al., (2009). Interactions with LC3 and polyubiquitin chains link nbr1 to 
autophagic protein turnover. FEBS Lett. 583, 1846-52. 
 Wei, Q., & Adelstein, R. S. (2000). Conditional expression of a truncated fragment of 
nonmuscle myosin II-A alters cell shape but not cytokinesis in HeLa cells. Molecular 
biology of the cell, 11(10), 3617–3627. 
Wild, P., Farhan, H., McEwan, D. G., Wagner, S., Rogov, V. V., Brady, N. R., et al. 
(2011). Phosphorylation of the autophagy receptor optineurin restricts Salmonella 
growth. Science (New York, NY), 333(6039), 228–233.  
Wilson, G.M. et al. (2005) The FIP3–Rab11 protein complex regulates recycling 
endosome targeting to the cleavage furrow during late cytokinesis. Mol. Biol. Cell 16, 
849–860.  
Xu, P., and Davis, R.J. (2010). c-Jun NH2-terminal kinase is required for lineage-specific 
differentiation but not stem cell self-renewal. Mol. Cell Biol. 30, 1329-40.  
Yamashita, Y.M., Jones, D.L. and Fuller, M.T. (2003). Orientation of asymmetric stem 
cell division by the APC tumor suppressor and centrosome. Science 301, 1547-50.  
Yamashita, Y.M., Mahowald, A.P., Perlin, J.R. and Fuller, M.T. (2007). Asymmetric 
inheritance of mother versus daughter centrosome in stem cell division. Science 315, 
518-21.  
Yorimitsu, T. and Klionsky, D.J. (2007). Eating the endoplasmic reticulum: quality 
control by autophagy. Trends Cell Biol. 17, 279-85.  
Yu, J. et al., (2007). Induced pluripotent stem cell lines derived from human somatic 
cells. Science 318, 1917-20.  
111
Yu, J. et al., (2009). Human induced pluripotent stem cells free of vector and transgene 
sequences. Science 324, 797-801.  
Yu, L. et al., (2004). Regulation of an ATG7-beclin 1 program of autophagic cell death 
by caspase-8. Science 304, 1500-2.  
Zhang, Y., Yan, L., Zhou, Z., Yang, P., Tian, E., Zhang, K., et al. (2009). SEPA-1 
mediates the specific recognition and degradation of P granule components by autophagy 
in C. elegans. Cell, 136(2), 308–321.  
Zhang J, Liu J, Huang Y, Chang JY, Liu L, McKeehan WL, Martin JF, Wang F (2012a) 
FRS2alpha- mediated FGF signals suppress premature differentiation of cardiac stem 
cells through regulating autophagy activity. Circ Res 110: e29-e39.  
Zhang J, Liu J, Liu L, McKeehan WL, Wang F (2012b) The fibroblast growth factor 
signaling axis controls cardiac stem cell differentiation through regulating autophagy. 
Autophagy 8: 690-691.  
Zhao, W.-M., Seki, A., & Fang, G. (2006). Cep55, a microtubule-bundling protein, 
associates with centralspindlin to control the midbody integrity and cell abscission during 
cytokinesis. Molecular Biology of the Cell, 17(9), 3881–3896.  
Zheng YT, Shahnazari S, Brech A, Lamark T, Johansen T, Brumell JH. The adaptor 
protein p62/SQSTM1 targets invading bacteria to the autophagy pathway. J Immunol 
2009; 183: 5909–5916.  
Zwaka, T.P. and Thomson, J.A. (2003). Homologous recombination in human embryonic 
stem cells. Nat. Biotechnol. 21, 319-21.  
Yang, Z., & Klionsky, D. J. (2010). Mammalian autophagy: core molecular machinery 
and signaling regulation. Current opinion in cell biology, 22(2), 124–131.  
Yuan, T. L., Wulf, G., Burga, L., & Cantley, L. C. (2011). Cell-to-cell variability in PI3K 
protein level regulates PI3K-AKT pathway activity in cell populations. Current biology : 
CB, 21(3), 173–183.  
 
